ПРОИЗВОДНЫЕ БЕНЗОТИАЗОЛА, ХАРАКТЕРИЗУЮЩИЕСЯ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ К БЕТА-2-АДРЕНОРЕЦЕПТОРАМ

Изобретение относится к соединениям общей формулы (I) и их фармацевтически приемлемым солям в качестве агонистов β2-адренорецептора, к способу их получения и применению, а также к фармацевтической композиции на их основе. Соединения могут найти применение для лечения состояний, которые можно предотвратить или снизить интенсивность симптомов при активации β2 -адренорецептора, например обструктивных или воспалительных заболеваний дыхательных путей. В общей формуле (I) X означает -R1-Ar-R2 или -Ra-Y; Ar означает фенилен, необязательно замещенный группой из ряда: галоген, гидрокси, C1-С10алкил, C1-С10алкокси, фенил, C1-С10алкокси, замещенный фенильной группой, или фенил, замещенный C1-С10 алкоксигруппой; R1 и R2присоединены к соседним атомам углерода в составе группы Ar, и либо R1 означает C1-С10алкилен, a R2 означает водород, C1-С10алкил или галоген, Ra означает связь или C1-С10алкилен, необязательно замещенный группой из ряда: гидрокси, C1-С10алкокси, C6-С10арил или C7-С14аралкил; Y означает ...

ОФТАЛЬМИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АСКОМИЦИН

Настоящее изобретение относится к применению местной офтальмической композиции, включающей аскомицин и носитель. Носитель включает триглицерид жирной кислоты со средней цепью, представляет основу для мази, а также может включать воду и эмульсификатор, консервант. Изобретение обеспечивает применение композиции для приготовления лекарственного средства для лечения себорейного, аллергического и стафилоккокового блефарита. 11 з.п. ф-лы.

АЗАИНДОЛЫ

Изобретение относится к фармацевтической композиции, ингибирующей протеинкиназу, включающей ингибирующее селективную киназу количество соединения общей формулы (I): где: R1 означает арил или индолил, причем последний необязательно замещен одной или более групп, выбранных из R4, -C(=O)-R, -C(=O)-OR5, -C(=O)-NY1Y2и -Z2R; R2 означает H; R3 означает Н; R4 означает С1-С6 алкил, необязательно замещенный одним заместителем -C(=O)-NY1Y2; R5 означает Н; R7 означает С1-С8алкил; R означает C1-С6алкил; X1 означает С-арил, С-гетероарил, такой как пиридил или изоксазолил, причем последний может быть необязательно замещен одним или двумя С1-С6алкилами, С-гетероциклоалкил, такой как морфолинил или пиперидинил, С-галоген, C-CN, С-ОН, C-Z2R, C-C(=O)-OR5, C-NY1Y2, C-C(=O)-NY1Y2; Y1 и Y2 независимо означает Н, арил, С3-С6 циклоалкил, C1-С6 алкил, необязательно замещенный одной группой, выбранной из фенила, галогена, гетероциклила, такого как морфолинил, фурил, гидрокси, -C(=O)-OR5, OR7; или группа -NY1Y2 может ...

ШТАММ LACTOBACILLUS CRISPATUS KBL693 И ЕГО ПРИМЕНЕНИЕ

Настоящее изобретение относится к области биотехнологии, а именно к штамму Lactobacillus crispatus KBL693 и к его применению. Штамм Lactobacillus crispatus KBL693 (идентификационный номер KCTC 13519BP) в соответствии с настоящим изобретением ослабляет аллергические клеточные реакции, значительно улучшает симптомы атопического дерматита и обладает противовоспалительным и противогрибковым действием. Таким образом, указанный одиночный штамм сам по себе может обеспечивать достижение всех целей смягчения атопического дерматита и других аллергических заболеваний и улучшения состояния при воспалительных заболеваниях и аутоиммунных заболеваниях и за счет этого успешно находить применение в качестве пробиотического вещества. Кроме того, указанный штамм на основании его противогрибковой активности можно успешно использовать в качестве средства для наружной обработки кожи против различных заболеваний кожи, вызванных грибками, а также в косметической композиции и функциональном пластыре для смягчения ...

НОВЫЕ ПЯТИЧЛЕННЫЕ ГЕТЕРОЦИКЛЫ, ИХ ПОЛУЧЕНИЕ, ИХ ПРИМЕНЕНИЕ И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ

Изобретение относится к новым пятичленным гетероциклическим соединениям общей формулы I: в которой W обозначает R1-A-C(R13); Y обозначает карбонильную группу; Z обозначает N(Rо); А обозначает фенилен; E обозначает R10CO; В обозначает (С1-С6)-алкилен, который может быть незамещенным или замещенным (С1 -С6)-алкилом; R0 обозначает в случае необходимости замещенный в арильном остатке (С6-С14)-арил-(С1-С8)-алкил; Rобозначает Н или (С1-С6)-алкил; R1 обозначает X-NH-C(=NH)-(CH2)p; p = 0; X обозначает водород, -ОН, (С1-С6)-алкоксикарбонил или в случае необходимости замещенный в арильном остатке феноксикарбонил или бензилоксикарбонил; R2, R2a, R2b обозначают водород; R3обозначает R11 NH- или CO-R5-R6-R7; R4 обозначает двухвалентный(С1 -С4)-алкиленовый остаток; R5обозначает двухвалентный остаток природной или неприродной аминокислоты с липофильной боковой цепью, выбранной из группы, состоящей из (С1 -С6)-алкильных остатков, (С6-С12)-арил-(С1-С4)-алкильных остатков, в случае необходимости замещенныхв ...

ПРОИЗВОДНОЕ ХИНАЗОЛИНА И ФАРМАЦЕВТИЧЕСКИЙ ПРЕПАРАТ

Настоящее изобретение относится к производному хиназолина, представленному общей формулой [1], или его фармацевтически приемлемой соли ! , где R1-R6 имеют значения, представленные в п.1 формулы, за исключением соединения, в котором R5 представляет собой водород, и R6 представляет собой -NH2. Изобретение также относится к фармацевтической композиции, обладающей активностью противозудного средства, содержащей в качестве активного ингредиента указанное выше производное хиназолина или его фармацевтически приемлемую соль. Технический результат - получение нового производного хиназолина с меньшим раздражающим действием на кожу и превосходным действием существенного подавления поведения расчесывания, а также противозудного средства, содержащего такое производное хиназолина в качестве активного ингредиента. 2 н. и 7 з.п. ф-лы, 250 пр., 7 табл.

БЕНЗИМИДАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Настоящее изобретение относится к новым производным бензимидазола общей формулы (I) или к его фармакологически приемлемым солям, где R' представляет собой С6-арильную группу, которая может быть замещенной 1-3 группами, независимо выбранными из группы заместителей (а), или гетероциклическую группу, которая представляет пиридил, дигидробензофуранил, 1,3-бензодиоксолил, тетрагидропиранил, тетрагидрофуранил, которая может быть замещенной 1-3 группами, независимо выбранными из группы заместителей (а), R2 представляет собой C1-С6 алкильную группу, R3 представляет собой С6-арильную группу, которая может быть замещенной 1-2 группами, независимо выбранными из группы заместителей (a), Q представляет собой группу, представленную формулой =СН-, или атом азота и группа заместителей (а) представляет собой группу, состоящую из атома галогена, C1-С6 алкильной группы, C1-С6 галогенированной алкильной группы, карбоксильной группы, C1-C7 алкилкарбонильной группы, C2-C7 алкоксикарбонильной группы, C1-С6 алкоксигруппы ...

ПРОИЗВОДНЫЕ МОЧЕВИНЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ

Изобретение относится к новым производным мочевины общей формулы (I) и их фармацевтически приемлемым солям, где А представляет собой -СН- или атом азота, R1 представляет собой С3-10 алкил, С3-10циклоалкил, С3-10циклоалкил-С1-10алкил, 6-членный азотсодержащий гетероциклил, 6-членный азотсодержащий гетероциклил-С1-10 алкил, фенил, фенил-С1-10алкил, 5-10-членный гетероарил или 5-10-членный гетероарил-С1-10алкил и др.; R2 представляет собой водород, С1-6алкил, С0-2 алкил-С3-10циклоалкил, С0-2алкил-фенил, С3-10циклоалкил-С0-2алкил или фенил-С0-2алкил; R5 представляет собой C1-6алкил, С3 -10циклоалкил, 6-членный азотсодержащий гетероциклил и др.; L1 представляет собой -S-, -S(О)-, -S(O)2, -С(O)-, -N(Rc)-, -CH2- и др.; L2 представляет собой ковалентную связь, -О-, -С(O)-, -ОС(O)-, -N(Rc)- и др.; W представляет собой О или S; Z представляет собой -C(O)ORd; Rc, Rd и Re представляют собой водород или алкил; Rb представляет собой -ORe, -NO2, галоген, -CN, -CF3, C1-6алкил; р представляет собой целое ...

ФАРМАЦЕВТИЧЕСКИЙ ПРЕПАРАТ, СОДЕРЖАЩИЙ ЦИКЛОСПОРИН, И ЕГО ПРИМЕНЕНИЕ

Данное изобретение относится к химико-фармацевтической промышленности и касается фармацевтического препарата в коллоидной форме для местного применения при лечении и профилактике патологических изменений кожи, и/или придатков кожи, и/или слизистых оболочек, включая слизистые оболочки желудочно-кишечного тракта, мочеполовых путей и бронхиальной системы, и/или конъюнктивы, содержащий липофильную фазу в количестве 1-10% по массе, смесь поверхностно-активного вещества и вспомогательного поверхностно-активного вещества, при этом поверхностно-активное вещество выбрано из эфиров полиоксиэтиленглицерина и жирных кислот и эфиров полиоксиэтиленсорбитана и жирных кислот, и вспомогательное поверхностно-активное вещество выбрано из полоксамеров, блок-сополимеров полиоксиэтилена и полиоксипропилена в количестве 1-50% по массе, гидрофильную фазу в количестве 40-80% по массе, и в качестве активного ингредиента циклоспорин или его производные в концентрации 0,1-20% по массе. 8 н. и 9 з.п. ф-лы, 5 табл., ...

ОФТАЛЬМОЛОГИЧЕСКАЯ КОМПОЗИЦИЯ С ВЫСОКОЙ КОНЦЕНТРАЦИЕЙ ОЛОПАТАДИНА

Группа изобретений относится к медицине, а именно к офтальмологии, и предназначена для лечения аллергического конъюнктивита глаз. Офтальмологическая композиция для лечения аллергического конъюнктивита глаз содержит по меньшей мере 0,67% масс./об., но не больше чем 1,0% масс./об. олопатадина, который растворен в растворе. Композиция помещена в глазной капельный дозатор для местного нанесения композиции в глаз в виде капель, которые имеют размер капли по меньшей мере 18 мкл, но не больше чем 45 мкл. Композиция имеет рН от 5,5 до 8,0. Дополнительно в состав композиции входят полиэтиленгликоль, поливинилпирролидон, и производное циклодекстрина в заявленных количествах. Также обеспечивается способ лечения симптомов аллергии глаз. Использование группы изобретений позволяет более эффективно уменьшать симптомы аллергического конъюнктивита глаз, в особенности симптомы поздней фазы аллергического конъюнктивита глаз. 5 н. и 20 з.п. ф-лы, 5 ил., 20 табл., 2 пр.

АМИНОВЫЕ СОЛИ АНТАГОНИСТА CRTH2

Изобретение относится к новым фармацевтически приемлемым солям, содержащим фармацевтически приемлемый амин, выбранный из этилендиамина, пиперазина, бензатина или холина, и {4,6-бис(диметиламино)-2-(4-(4-(трифторметил)бензамидо)бензил)пиримидин-5-ил}уксусную кислоту. Изобретение также относится к способу получения указанных солей, к фармацевтической композиции, содержащей указанные соли, и к применению соли для приготовления лекарственного средства для лечения, предупреждения или облегчения одного или нескольких симптомов заболевания, опосредованного CRTH2, связанного с эозинофилами, базофилами, где заболевание выбрано из астмы, аллергической астмы, астмы физического усилия, аллергического ринита, многолетнего аллергического ринита, сезонного аллергического ринита, атопического дерматита, контактной гиперчувствительности и гипер IgE синдрома. 8 н. и 35 з.п. ф-лы, 21 ил., 4 табл., 6 пр.

ЛЕКАРСТВЕННЫЙ ПРЕПАРАТ ПРОТИВОГИСТАМИННОГО ДЕЙСТВИЯ (ВАРИАНТЫ)

Препарат содержит, г: диазолин 0, 38 - 0,42, цинка сульфат 0,018 - 0,022, поливинилпирролидон с мол. м. 35000 ± 5000 0,047 - 0,053, крахмал картофельный 0,024 - 0,026 и кальция стеарат 0,002 - 0,005. Преимуществом лекарственного препарата является отсутствие раздражающего действия на желудочно-кишечный тракт, тормозящего влияния на центральную нервную систему, свойственного ряду используемых в настоящее время антигистаминных средств. 2 с.п.ф-лы.

ПРОИЗВОДНЫЕ N,N-ДИЭТИЛДИТИОКАРБАМИНОВОЙ КИСЛОТЫ, ОБЛАДАЮЩИЕ ПРОТИВОАЛЛЕРГИЧЕСКОЙ АКТИВНОСТЬЮ

Настоящее изобретение относится к производным N,N-диэтилдитио-карбаминовой кислоты формулы I, в которой R имеет значения группы Iа. Соединения обладают противоаллергической активностью. 4 ил., 1 табл.

ПРОИЗВОДНЫЕ 7-(2-АМИНОЭТИЛ)БЕНЗОТИАЗОЛОНА ИЛИ ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, ПРОИЗВОДНЫЕ N-[2-(4-ГИДРОКСИ-2-ОКСО-3H-1,3-БЕНЗОТИАЗОЛ-7-ИЛ)ЭТИЛАМИДА]ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ПРОЯВЛЯЮЩАЯ АГОНИСТИЧЕСКУЮ АКТИВНОСТЬ В ОТНОШЕНИИ β2-АДРЕНОРЕЦЕПТОРОВ

Использование: в химии гетероциклических соединений, проявляющих агонистическую активность в отношении β2-адренорецепторов. Сущность изобретения: производные 7-(2-аминоэтил)бензтиазолона формулы I где X и Y независимо означают -S(O)n- или -O-, n означает 0,1 или 2, p, q и r независимо означают 2 или 3, Z означает фенил с возможным замещением галогеном, -OR1, NO2 или NH2 или Z представляет собой 5- или 6-членный ненасыщенный гетероцикл, содержащий N или S, при этом R1 означает водород или алкил C1 - C6 или их фармацевтически приемлемые соли. Описаны способы их получения и содержащие их фармацевтические композиции, а также промежуточные соединения для их получения формулы Va где p, q и r, X, Y имеют указанные значения, а Z - фенил, необязательно замещенный атомом галогена, NO2, NH2 или OR1, где R1 - H или C1 - C6-алкил. 4 с. и 7 з.п.ф-лы, 3 табл.

Средство гуминовой природы, обладающее противоаллергической активностью

Изобретение относится к области медицины, а более конкретно к клинической иммунологии и поиску новых средств противоаллергического действия, и может быть использовано для фармакологической коррекции нарушений системы иммунитета, связанных с повышенной секрецией иммуноглобулина Е. Водорастворимые гуминовые кислоты, выделенные экстракцией натрий пирофосфатом из верхового сосново-пушицевого торфа, применяют, например, в качестве средства, обладающего противоаллергической активностью, причем при курсовом приеме они обладают способностью подавлять развитие ранних стадий аллергических реакций Th2-зависимого типа иммунного ответа посредством уменьшения тяжести протекания системной реакции анафилаксии, снижения концентрации иммуноглобулинов класса Е и стабилизации мембран тучных клеток. Задачей данного изобретения является расширение арсенала нетоксичных противоаллергических средств природного происхождения. Принципиально новым в предлагаемом изобретении является применение в качестве противоаллергического ...

КАПЛИ ПЕТРОСЯНА N 1Б (2Б-7Б ИХ ВАРИАНТЫ) ДЛЯ ЛЕЧЕНИЯ АЛЛЕРГИЧЕСКИХ И НЕАТОПИЧЕСКИХ ЗАБОЛЕВАНИЙ ГЛАЗ И НОСА

Изобретение относится к медицине, к лечению аллергических и неатопических заболеваний глаз и носа. Капли Петросяна 1Б включают кромолин или недокромил натрий или кромоглициевую кислоту, дексаметазон-21-фосфат натриевую соль, борную кислоту и стерильный буферный раствор. Капли Петросяна 3Б включают вместо дексаметазона-21-фосфат натриевой соли - димедрол, а капли Петросяна 7 Б - эфедрина гидрохлорид. Преимуществами предлагаемых композиций являются более высокая эффективность, антибактериальное и противогрибковое действие, более низкие побочные эффекты. Указанные капли применяются по 1-2 капли в обе половины носа и/или в оба глаза 4-5 раз в день. Применение капель имеет ограниченные противопоказания, может вызывать кратковременное жжение. 3 с. и 4 з.п. ф-лы.

ПРОИЗВОДНЫЕ ТРИАЗАСПИРО[5.5] УНДЕКАНА И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ВКЛЮЧАЮЩАЯ ЕГО В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА

... 1. Производное триазаспиро[5.5]ундекана формулы (I) где R1 имеет формулу (1) или (2) где G представляет связь, С1-4 алкилен, С2-4 алкенилен, или -СО-; кольцо А представляет собой (1) С5-10-членное моно- или бикарбоциклическое кольцо или (2) 5-10-членный моно- или бициклический гетероцикл, содержащий 1-2 атома азота и/или 1-2 атома кислорода; R6 представляет (1) С1-4алкил, (2) галоген, (3) нитрил, (4) трифторметил, (5) -OR8, (6) -SR9, (7) -NR10R11, (8) -COOR12, (9) -CONR13R14, (10) -SO2NR15R16, (11) NR17SO2R18, (12) -S(O)R19, (13) -SO2R20, (14) -N(SO2R21)2, (15) С1-4алкил, замещенный заместителем, выбранным из (а) -OR8, (b) -NR10R11, и (с) Сус 1, или (16) -NR27COR28, где R8-R17 каждый независимо представляет (1) водород, (2) С1-4алкил, (3) Сус 1, (4) -OR22, и (5) C1-4алкил, замещенный заместителем, выбранным из (a) -OR22, (b) -NR23R24, (с) -COOR25 и (d) Сус 1, или R10 и R11, R13 и R14 или R15 и R16, каждый независимо, вместе с атомом азота, к которому они присоединены, образуют 5-6-членный ...

ПРОИЗВОДНЫЕ НИКОТИНАМИДА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ Р38-ИНГИБИТОРОВ

... 1. Соединение формулы (I) где R1 выбран из водорода, С1-6алкила, возможно замещенного группами в количестве до трех включительно, выбранными из С1-6алкокси, галогена и гидрокси, С2-6алкенила, С3-7 циклоалкила, возможно замещенного одной или более чем одной С1-6алкильной группой, фенила, возможно замещенного группами в количестве до трех включительно, выбранными из R5 и R6, и гетероарила, возможно замещенного группами в количестве до трех включительно, выбранными из R5 и R6; R2 выбран из водорода, С1-6алкила и -(CH2)q-C3-7циклоалкил, возможно замещенного одной или более чем одной С1-6алкильной группой, или (СН2)mR1 и R2 совместно с атомом азота, к которому они присоединены, образуют (четырех-шести)членное гетероциклическое кольцо, возможно замещенное С1-6алкильными группами в количестве до трех включительно; R3 представляет собой хлоро или метил; R4 представляет собой группу -NH-CO-R7 или -CO-NH-(CH2)q -R8; R5 выбран из С1-6алкила, С1-6алкокси, -{СН2)q-С3-7циклоалкил, возможно замещенного ...

ПРОИЗВОДНЫЕ ТРИАЗАСПИРО[5.5]УНДЕКАНА И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ЭТИ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ АКТИВНОГО ИНГРИДИЕНТА

... 1. Производное триазаспиро[5.5]ундекана формулы (I) [где R1 представляет (1) водород, (2) C1-18-алкил, (3) С2-18-алкенил, (4) С2-18-алкинил, (5) - COR6, (6) - CONR7R8, (7) - COOR9, (8) - SO2R10, (9) - COCOOR11, (10) - CONR12COR13, (11) Сус 1 или (12) C1-18-алкил, C2-18 -алкенил или С2-18-алкинил, замещенные 1-5 заместителями, необязательно выбранными из (а) галогена, (b) - CONR7R8, (с) - COOR9, (d) - OR14, (e) - SR15, (f) - NR16R17, (g) - NR18COR19, (h) - SO2NR20R21 (i) - OCOR22, (j) - NR23SO2R24 (k) - NR25COOR26, (1) - NR27CONR28R29, (m) Cyc 1, (n) кето или (о) - N(SO2R24)2, (где каждый из R6-R9, R11-R21, R23, R25 и R27-R29 независимо представляет (1) водород, (2) C1-8-алкил, (3) С2-8-алкенил, (4) C2-8-алкинил, (5) Сус 1 или (6) C1-8-алкил, С2-8-алкенил или С2-8-алкинил, замещенные 1-5 заместителями, необязательно выбранными из (а) Сус 1, (b) галогена, (с) - OR30, (d) - SR31, (е) - NR32R33, (f) - COOR34, (g) - CONR35R36, (h) - NR37COR38, (i) - NR39SO2R40 или (j) - N(SO2R40)2, или R7 и ...

ФАРМАЦЕВТИЧЕСКИЕ ПРИМЕНЕНИЯ ФЕРМЕНТНОЙ КОМПОЗИЦИИ, ВЫДЕЛЕННОЙ ИЗ АНТАРКТИЧЕСКОГО КРИЛЯ

Неиммуногенные ферментные композиции, выделенные из антарктического криля и проявляющие как эндо-, так и экзопептидазную активность, применимы для приготовления лекарственных препаратов и фармацевтических композиций для лечения большого разнообразия заболеваний человека и животных, таких как инфекции, воспаления, раковые заболевания, ВИЧ/СПИД, боль, полипы, бородавки, геморрои, бляшки, морщины, утончение волос, аллергический зуд, спайкообразование, глазные болезни, такие как катаракта, глаукома, и т.д.

ТРАНСГЕННЫЕ РАСТЕНИЯ, ЭКСПРЕССИРУЮЩИЕ ТЕРАПЕВТИЧЕСКИ АКТИВНЫЕ ПРОТЕИНЫ

... 1. Растение, в пластидный геном которого включена молекула ДНК, кодирующая протеин, который является терапевтически активным при введении хозяину, нуждающемуся в этом, в терапевтически эффективном количестве, где растение обладает способностью экспрессировать указанный протеин. 2. Растение по п.1, где протеин вводят хозяину перорально. 3. Растение по п.1, где протеин представляет собой антиген. 4. Растение по п.3, где антиген обладает способностью подавлять или снижать иммунный ответ или воспалительное состояние у указанного хозяина, вызванные антигеном. 5. Растение по п.4, где антиген представляет собой аллерген. 6. Растение по п.5, где аллерген представляет собой ингаляционный аллерген. 7. Растение по п.5, где аллерген представляет собой аллерген пыльцы. 8. Растение по п.7, где аллерген пыльцы выбирают из группы, включающей аллергены амброзии Amb a I, Amb a I.1, Amb t V и Amb a II, аллерген ольхи Ain g I, аллерген лещины Cor a I, аллерген плевела Lol p V, аллерген джонсоновой травы Sor ...

ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЛИПИДЫ, КОТОРЫЕ НЕСУТ ПОЛЯРНЫЙ И НЕПОЛЯРНЫЙ ФРАГМЕНТ

... 1. Композиция, содержащая (I) соединение, представляющее собой липид, который содержит по меньшей мере один неполярный фрагмент и полярный фрагмент, где неполярный фрагмент представлен формулой X-Y-Z-, где Х обозначает ацетиленовую гидрокарбильную группу, содержащую одну связь С=С, Y обозначает О или СН2 и Z обозначает необязательную гидрокарбильную группу, в которой полярный фрагмент представлен формулой - [T]mПГГ, где [T]m обозначает необязательную группу, выбранную из ряда, включающего С(O), NH, NR1, NHC(O), C(O)NH, NR1C(O), C(O)NR1 и CH2, где R1 обозначает гидрокарбильную группу, где ПГГ обозначает полярную головную группу, и где m обозначает количество неполярных фрагментов, (II) терапевтический агент. 2. Композиция по п.1, где соединение представляет собой нейтральный липид. 3. Композиция по п.1, где соединение представляет собой катионный липид. 4. Композиция по п.1, где соединение имеет формулу где р обозначает 1-10, предпочтительно 1, 2 или 3, и где каждый X, Y и Z выбирают независимо ...

Способ получения производных бензимидазола или их солей

Способ получения сесквитерпенового производного

Способ получения производных бензопирана или их солей

Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate

WAESSRIGES NATRIUMCROMOGLYCAT ENTHALTENDE MITTEL.

MITTEL, ENTHALTEND EINEN CYCLOOXYGENASE-2 INHIBITOR UND EINEN 5-LIPOXYGENASE INHIBITOR

IMIDAZOLDERIVATE ALS HISTAMIN-H3-MODULATOREN

1,2,4-TRIAZOLO[4,3-B]PYRIDO[3,2-D]PYRIDAZINDERIVATE UND DIESE ENTHALTENDE PHARMACEUTISCHE ZUBEREITUNGEN

ESTROGEN-17-SULPHAMATE ZUR HEMMUNG VON STEROID SULFATASE

4,6-DIPHENYLPYRIDINDERIVATE ALS ENTZÜNDUNGSHEMMENDE MITTEL

Wipes

Benzoic acid derivatives useful as intermediates

Aromatic heterocyclic derivatives have the formula wherein R1 represents wherein R3 represents hydrogen, -OR4 wherein R4 represents hydrogen, alkyl having 1-20 carbon atoms or mono- or polyhydroxyalkyl or R3 represents wherein r' and r'' represent hydrogen, lower alkyl or together form a heterocycle, R2 represents hydrogen or -CH3 and Ar represents (A) (B) wherein Z is O or S, (C) wherein R5 is lower alkyl or (D) wherein R6 is hydrogen or alkyl having 1-10 carbon atoms and R7 represents alkyl having 4-12 carbon atoms or cycloalkyl, Y is CH or a nitrogen atom and X represents oxygen, sulfur or -N-R8 when R8 represents hydrogen, lower alkyl or lower alkoxycarbonyl, with the proviso that (i) when Y is CH and X is oxygen or sulfur Ar is other than C and (ii) when Y is nitrogen and X is oxygen, Ar is other than (C) or (D) in which R6 is alkyl having 1-4 carbon atoms and R7 is branched alkyl having 4-12 atoms useful in veterinary or human therapy and in cosmetic formulations.

1-SUBSTITUTED DERIVATIVES OF 4-METHOXY-2, 3, 6-TRIMETHYLBENZENE, PROCESS FOR THEIR PREPARATION AND MEDICINAL AND COSMETIC COMPOSITIONS CONTAINING THEM

NEW BENZOFURAN DERIVATIVES, THE PROCESSES FOR PREPARING THEM AND MEDICINAL AND COSMETIC COMPOSITIONS CONTAINING THEM

Chemical compounds

Azaindoles.

Preventative treatment and remission of allergic diseases

Phenethanolamine derivatives for treatment of respiratory diseases.

Phenethanolamine derivatives for treatment of respiratory disease.

Pyrropyrimidines as protein kinase inhibitors.

Azaindoles.

Azaindoles

Pyrrolo[2,3d] pyrimidine compositions and their use.

Novel deazapurines are disclosed which are useful for the treatment of adenosine receptor stimulated diseases.

Tetracyclic derivatives, process of preparation and use.

A compound of formula (1) ...

Tetracyclic derivatives, process of preparation and use

Pyrimidinyl carboxamides useful as inhibitors of PDE4 isozymes.

Compounds of formula (1.0.0) are discribed, as well as the usefulness of a pharmaceutical composition for treating inflammatory, respiratory and allergic diseases and conditions, especially asthma; chronic obstructive pulmonary disease (COPD) including chronic bronchitis, emphysema, and brochiectasis; chronic rhinitis, and chronic sinusitis.

Azaindoles

Preventative treatment and remission of allergic diseases

Pyrrolo¬2,3d¾pyrimidine compositions and their use

Azaindoles.

Preventative treatment and remission of allergic diseases

Azaindoles.

Pyrrolopyrimidines as protein kinase inhibitors

This invention is directed to compounds of the formula (I) to N-oxides, prodrugs, acid bioisosteres, pharmaceutically acceptable salts or solvates of such compounds, or N-oxides, prodrugs, or acid bioisosteres of such salts or solvates, to compositions comprising such compounds, and to methods of treatment comprising administering, to a patient in need thereof, such compounds and compositions.

Combination of azelastine and steroids.

Phenethanolamine derivatives for treatment of respiratory disease.

Azaindoles

Phenethanolamine derivatives for treatment of respiratory diseases

Pyrrolopyrimidines as protein kinase inhibitors.

Tetracyclic derivatives process of preparation anduse

Derived from hétérocyclyl-carboxylic acids acylés and proceeded for their preparation.

PyrroloÄ2,3dÜpyrimidine compositions and their use.

New derivatives of the benzopyranne and their method of preparation.

Azaindoles.

Azaindoles.

Pyrimidine carboxamides useful as inhibitors of PDE4 isozymes.

Combination of azelastine and steroids.

Pyrropyrimidines as protein kinase inhibitors.

Azaindoles

Azaindoles.

Azaindoles

Pyrimidinyl carboxamides useful as inhibitors of pde4 isozymes

Pyrrolo¬2,3d¾pyrimidine compositions and their use

Combination of azelastine and steroids.

Tetracyclic derivatives, process of preparation and use

Azaindoles.

Azaindoles.

Pyrimidinyl carboxamides useful as inhibitors of pde4 isozymes

Pyrrolo¬2,3d¾pyrimidine compositions and their use

Phenethanolamine derivatives for treatment of respiratory disease.

Preventative treatment and remission of allergic diseases

CONDENSED POLYCYCLI CONNECTIONS

ANTI-INFLAMMATORY 7.BETA. - CARBOTHIOATE of ESTER DERIVATIVES OF ANDROSTAN WITH a 17.ALPHA. - CYCLIC GROUP OF ESTERS

SCREENINGVERFAHREN FOR SUITABLE ACTIVE SUBSTANCES

NEW DERIVATIVES OF FLAVON C GLYCOSIDE AND COMPOSITION, WHICH CONTAIN THESE DERIVATIVES

PROCEDURE FOR THE PRODUCTION OF NEW BENZOPYRANDERIVATE AND YOUR SALTS

LYMPHOZYTEN FUNCTION ANTIGEN-1 ANTAGONISTS

VERFAHREN ZUR HERSTELLUNG VON NEUEN DICHLORANILINDERIVATEN

The invention provides compounds of the general formula (I) (I) wherein X represents a bond or a C1-6 alkylene, C2-6 alkenylene or C2-6 alkynylene chain, and Y represents a bond, or a C1-4 alkylene, C2-4 alkenylene or C2-4 alkynylene chain with the proviso that the sum total of carbon atoms in X and Y is not more than 8; Py represents a pyridyl group optionally substituted by one or two substituents selected from halogen atoms, hydroxy, C1-3 alkyl and C1-3 alkoxy groups; and R1 and R2 each represent a hydrogen atom or a C1-3 alkyl group, with the proviso that the sum total of carbon atoms in R1 and R2 is not more than 4; and physiologically acceptable salts and solvates (e.g. hydrates) thereof. The compounds have a stimulant action at beta 2-adrenoreceptors and may be used in the treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis.

CONDENSED PYRIMIDINE AS AN ANTAGONIST OF THE CORTICOTROPIN RELEASING FACTOR (CRF)

METHODS AND COMPOSITIONS FOR THE MODULATION OF THE ACTIVITY THE ALPHA ADRENERGEN RECEPTORS

PROCEDURE FOR THE PRODUCTION OF NEW BENZOPYRANDERIVATE AND THEIR SALTS

UREA OF DERIVATIVES AS INTEGRIN ALPHA 4 ANTAGONISTS

2-PHENYLINDOLE AS ANTAGONISTS of the PROSTAGLANDIN-D2-REZEPTORS

COMPOSITIONS FOR THE TRANSMUKOSALE ADMINISTRATION WITH COENZYM Q AS ACTIVE SUBSTANCE

COMBINATIONS FOR THE TREATMENT OF MULTIPLE MYELOM

Non-sedating antihistamine injection formulations and methods of use thereof

Described herein are injectable compositions containing non-sedating or second and third generation antihistamines such as cetirizine/levocetirizine and methods of use thereof. Specifically, methods of treating acute urticaria or angioedema associated with an acute allergic reaction are disclosed. In certain embodiments, the injectable compositions are bioequivalent to currently marketed oral dosage forms with the same number of mg of cetirizine.

METHODS FOR TREATING IgE-MEDIATED DISORDER

This invention relates to methods of treating IgE mediated disorders such as allergy and asthma based on activating surface-bound IgD molecules on basophils. The invention also relates to methods of making IgD, as well as methods of screening for antimicrobial agents from IgD-activated basophils.

Storage-stable aqueous ophthalmic formulations

Storage-stable, topically ocularly administrable aqueous ophthalmic formulations containing at least one closporine are useful for treating and/or preventing ophthalmic diseases or disorders afflicting humans or animals, notably related to inflammatory conditions, more particularly administrable to the front of the eye and which provide therapeutic effects to the eye as they are effective in stabilizing, enhancing and/or improving a patient's vision.

Geographically Region Specific Allergy Immunotherapy for Companion Animals

Implementations and techniques for providing geographically region specific allergy immunotherapy for companion animals are generally disclosed.

Hmg-coa reductase derived peptide and cosmetic or pharmaceutical composition containing same

The present invention relates to a peptide of general formula (I): R 1 -(AA) n -X 1 -Gly-Glu-Leu-Ser-X 2 -X 3- (AA) p -R 2 , derived from human HMG-CoA reductase. The present invention also relates to a cosmetic or pharmaceutical composition comprising at least one peptide of general formula (I), in a physiologically suitable medium. The present invention further relates to the use of this novel peptide as an active principle that activates human HMG-CoA reductase in a cosmetic composition intended to strengthen the barrier function of the skin and to stimulate epidermal differentiation. The invention further applies to a cosmetic treatment method intended to prevent and/or combat the external stresses and signs of cutaneous aging.

Oral pharmaceutical composition for use in respiratory diseases

A modified-release oral pharmaceutical composition in capsules with microspheres contains loratadine, phenylephrine and pharmaceutically acceptable excipients. The composition has immediate bioavailability, with plasmatic concentration values within the therapeutic window with a uniform, continuous release. A method for the production of the composition and a method for treatment as a nasal decongestant and an antihistamine are included.

Emulsion Method For Preparing Low Residual Solvent Microparticles

The method disclosed herein comprises using a non-polar alkane in the continuous phase of an emulsion process to aid in the removal of dispersed phase solvent from the microparticles. The microparticles can further be subjected to a post-production treatment process, involving a non-polar alkane suspension and a rinse, to further reduce residual dispersed phase solvent levels.

Methods of using il-31 to treat chronic obstructive pulmonary disease (copd)

Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proinflammatory cytokines and include administration of the IL-31 agonist during sensitization or challenge resulting in the asthma, airway hyper-responsiveness or allergic rhinitis state.

Nasal spray device

A nasal spray device for the delivery of a pharmaceutical formulation to the nasal cavity in metered doses. The device includes: a pressurised aerosol canister including a vial containing a pharmaceutical formulation including an active ingredient, a propellant and, optionally, a co-solvent, the aerosol canister further including a metering valve having a valve stem; and an actuator for the aerosol canister, the actuator including a stem block having a receptacle into which the valve stem of metering valve of the aerosol canister is received and axially located and being displaceable relative to the vial of the aerosol canister to actuate the metering valve of the aerosol canister, a sump extending below the receptacle, the stem block further defining a discharge orifice for the pharmaceutical formulation and a transfer channel through which a dispensed dose of the pharmaceutical formulation is able to pass from the sump to the discharge orifice.

Novel caviidae allergens and uses thereof

The present invention relates to the provision of a nucleic acid molecule encoding a Caviidae allergen comprising a polynucleotide selected from the group consisting of (a) a polynucleotide sequence as shown in SEQ ID NO 1 (Cav p 3), SEQ ID NO 5 (Cav p 2), SEQ ID NO 3 (Cav p 6) or SEQ ID NO 19 ( Cavia porcellus allergen 1 a) or a fragment thereof, (b) a polynucleotide sequence encoding a polypeptide as shown in SEQ ID NO 2 (Cav p 3), SEQ ID NO 6 (Cav p 2), SEQ ID NO 4 (Cav p 6) or SEQ ID NO 20 ( Cavia porcellus allergen 1 a) or a fragment thereof (c) a polynucleotide sequence which has at least 80% identity to the polynucleotides as defined in (a) or (b) encoding a Caviidae allergen or a fragment thereof, (d) a polynucleotide sequence encoding a polypeptide which has at least 85% identity to the polypeptide as shown in SEQ ID NO 2 (Cav p 3), SEQ ID NO 6 (Cav p 2), SEQ ID NO 4 (Cav p 6) or SEQ ID NO 20 ( Cavia porcellus allergen 1 a ) or a fragment thereof, (e) a polynucleotide sequence which hybridizes to the polynucleotide sequence of any one of (a) to (d) and whereby the coding strand encodes a Caviidae allergen or a fragment thereof, (f) a polynucleotide sequence encoding a polypeptide as encoded by the nucleotide sequence of any one of (a) to (e) wherein at least one amino acid is deleted, substituted inserted or added and whereby said polynucleotide encodes a Caviidae allergen or a fragment thereof, and (g) a polynucleotide sequence being degenerate as a result of the generic code to the polynucleotide sequence as defined in any one of (a) to (f) The present invention also provides for a method for producing the polypeptides (Cav p3, Cav p6, Cavia porcellus allergen 1 a) encoded by said polynucleotides Moreover, the use of such allergens in a medical setting (e g in form of a pharmaceutical and/or diagnostic composition) an in vitro method for determining the allergenicity to Caviidae as well as an method for identifying potential antagonists or agonists of the ...

Pure isomers of tritoqualine

The invention provides an isolated stereoisomer of tritoqualine having the structure of FIG. 2 and FIG. 3.

New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders

The present invention provides pharmaceutical compositions comprising one or more CRTH2 antagonists 1 and one or more further active compounds 2.

Azaindazoles as kinase inhibitors and use thereof

Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, (I) are useful as kinase modulators, including Btk modulation, wherein A 1 , A 2 , A 3 , R 4 are as defined herein.

Non-flammable insecticide composition and uses thereof

The present invention provides a safe and effective insecticide composition suitable for treating a subject infested with a parasitic anthropode or to prevent infestation by an arthropod. The insecticide composition is a foamable composition, including a first insecticide; at least one organic carrier selected from a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 5%, or about 5% to about 10%; or about 10% to about 20%; or about 20% to about 50% by weight; about 0.1% to about 5% by weight of a surface-active agent; about 0.01% to about 5% by weight of at least one polymeric agent selected from a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent; and (5) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.

Heterocyclylaminopyrimidines as kinase inhibitors

The invention relates to compounds of formula (I) wherein R 1 to R 6 and T 0 have the meaning as cited in the description and the claims. Said compounds are useful as inhibitors of ZAP-70, Syk or JAK3 for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.

Bepotastine compositions

Novel compositions including bepotastine besilate are provided such as sorbitol-free compositions, compositions including at least about 0.008% w/v benzalkonium chloride, and compositions including hydroxypropylmethyl cellulose E15 LV.

Methods and compositions for promoting the respiratory development of an infant

The present invention relates to methods for promoting respiratory development, reducing the incidence of respiratory distress, bronchopulmonary dysplasia and/or hayfever in an infant by administration of fatty acids and compositions comprising same, wherein the fatty acids are enriched with respect to docosahexaenoic acid (DHA) content.

Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions

A method of combating rheumatoid arthritis, comprising administering to a human subject in need thereof, an effective oral dose of a probiotic composition in an oral dose form including, as the only bacterial species therein, the bacterial species of Bacillus subtilis, Bacillus coagulans , and Enterococcus faecium . The initial occurrence, and progress of remission of the rheumatoid arthritis condition incident to such probiotic therapy, may be established and monitored by assay of rheumatoid factor and/or anti-CCP antibodies present in a blood sample of the human subject.

RNAi-Mediated Inhibition of Histamine Receptor H1-Related Conditions

RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.

Interleukin-21 receptor binding proteins

The present invention provides binding proteins and antigen-binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing and/or treating IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.

Compositions and methods for treating airway inflammatory diseases

A composition for treating an airway inflammatory disease having high molecular weight, crosslinked hyaluronan and at least one aeroallergen is provided. A method of inducing immune tolerance to one or more aeroallergens in a mammalian subject suffering from or at risk of developing an airway inflammatory disease, and a method of treating a human subject suffering from or at risk of developing an airway inflammatory disease or condition of the lungs are also provided.

Bepotastine compositions

Novel compositions including bepotastine besilate and a corticosteroid are provided, compositions including at least about 0.008% w/v benzalkonium chloride, and compositions including hydroxypropylmethyl cellulose E15 LV.

Anti-allergic agent

According to the present invention, an anti-allergic agent is provided which includes a polysaccharide comprising galactose, glucose and rhamnose as constituents, or includes a microorganism belonging to a genus Bifidobacterium and extracellularly producing the polysaccharide. The anti-allergic agent of the present invention can be used in oral compositions and compositions for external application, and is suitable for use in products such as food products, pharmaceutical products, and cosmetics.

Dp2 antagonist and uses thereof

Described herein is the DP 2 anatgonist 2-(3-(2-((tert-butylthio)methyl)-4-(2,2-dimethyl-propionylamino)phenoxy)-4-methoxyphenyl)acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP 2 anatgonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP 2 anatgonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D 2 -dependent or prostaglandin D 2 -mediated diseases or conditions.

Pharamceutical compositions and methods of use 4-pregenen-11beta-17-21-triol-3,20-dione derivatives

The present invention relates to pharmaceutical compositions comprising 4-pregenen-11β-17-21-triol-3,20-dione derivatives, and their use as pharmaceuticals as modulators of the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR). The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat ocular conditions associated with the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR).

Microbial delivery system

The present invention provides methods and compositions for treating or preventing allergic responses, particularly anaphylactic allergic responses, in subjects who are allergic to allergens or susceptible to allergies. Methods of the present invention utilize administration of microorganisms to subjects, where the microorganisms produce allergens and protect the subjects from exposure to the allergens until phagocytosed by antigen-presenting cells. Particularly preferred microorganisms are gram-negative bacteria, gram-positive bacteria, and yeast. Particularly preferred allergens are proteins found in foods, venoms, drugs and latex that elicit allergic reactions and anaphylactic allergic reactions in individuals who are allergic to the proteins or are susceptible to allergies to the proteins. The proteins may also be modified to reduce the ability of the proteins to bind and crosslink IgE antibodies and thereby reduce the risk of eliciting anaphylaxis without affecting T-cell mediated Th1-type immunity.

Bicyclic heteroaryl inhibitors of pde4

The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.

Process for preparing carboxamidine compounds

The present invention relates to a process of making a compound of formula (I): Wherein, R 1 , R 2 , R 4 and X are as defined herein.

Kit providing multiple unmet therapeutic effects

The present invention discloses a unique kit for providing a combinational therapeutic product comprising a medical device and a pharmaceutical composition to treat mammal diseases. The medical device is to meet these unmet needs of cleansing out these harmful substances, such as viruses, multiple drug resistant bacteria, fungi, pollen, dusts, or excessive mucus. The pharmaceutical composition adds the required functions of anti-inflammatory, anti-allergy, anti-cancer, promoting membrane healing or immunomodulating, to have the added effect of the medical device. The method of using the combinational product is also disclosed. The new product can be used to prevent and treat a variety of diseases, such as common cold, drug resistant influenza, sinusitis, post nasal drip, virus-triggered asthma, or chronic obstructive pulmonary disease. In addition, the new kit and the process of use are safe and cost effective.

Hypoallergenic polypeptides for the treatment of house dust mite allergy

The present invention relates to a polypeptide comprising the amino acid sequence as shown in SEQ ID NO:9 or 7. The invention further pertains to nucleic acids encoding the polypeptide, pharmaceutical compositions and vaccines.

Use of a hypoallergenic cereal composition for inducing specific oral tolerance

A partial hydrolysate of cereal protein for use in inducing specific oral tolerance in a young mammal with allergy to said cereal protein, wherein the hydrolysate has a degree of hydrolysis between 9 and 18%, is disclosed.

Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity

The application is related to compositions and methods for the treatment of hypersensitivity, wherein the compositions comprise a particle packaged with immunostimulatory nucleic acids. The compositions of the invention are particularly useful in the treatment of atopic eczema, asthma and IgE-mediated allergy (type I allergy), especially pollen allergy and house dust allergy.

Biological inorganic compound complex having reduced oxygen and high reducing ability

Provided is an inorganic composite compound having reduced oxygen and a high reducing ability, which includes elements having a positive atomic valence of a plant-derived component and a sulfur compound. The compound provides a therapeutic treatment effect and a pharmacological effect and is useful to suppress the influence of active oxygen (oxidization) and cannot be produced by a synthetic chemical technique. A method of producing the same is also provided.

Lactobacillus Crispatus KBL693 Strain and Use Thereof

A strain of Lactobacillus crispatus KBL693 and the use thereof are disclosed. The strain of Lactobacillus crispatus KBL693 (Accession No. KCTC 13519BP) attenuates allergic reactions of cells, significantly improves symptoms of atopic dermatitis, and exhibits anti-inflammatory and anti-fungal effects. Thus, the single strain alone can achieve all the purposes of alleviating atopic dermatitis and other allergic diseases and improving inflammatory diseases and autoimmune diseases, thereby finding advantageous applications as a probiotic substance. In addition, the strain, based on the anti-fungal activity thereof, can be advantageously utilized in a skin external preparation against various skin diseases caused by fungi, and in a cosmetic composition and a functional patch for alleviating sensitive skin.

METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING THE DEVELOPMENT OF FOOD ALLERGIES

Described herein are methods and compositions for treating or preventing a food allergy. Aspects of the invention relates to administering to a subject an agent that induces a regulatory T cell, or population thereof, that expresses ROR yt. Another aspect of the invention relates to administering a fecal matter transplant to a subject having reduced ROR yt-expressing regulatory T cells to treat or prevent a food allergy. 1. A method for treating or preventing the onset of a food allergy in a subject , the method comprising: administering to a subject an agent that induces a regulatory T cell , or population thereof , that expresses RORγt.2. The method of claim 1 , further comprising claim 1 , prior to administration claim 1 , diagnosing a subject as having claim 1 , or likely to develop claim 1 , a food allergy claim 1 , or receiving the results of an assay that diagnoses a subject as having claim 1 , or likely to develop claim 1 , a food allergy.34.-. (canceled)5. The method of claim 1 , wherein the agent is administered prior to the first exposure to a potential food allergen claim 1 , or upon clinical signs of atopic symptoms.6. (canceled)7. The method of claim 1 , wherein the subject has been diagnosed with at least one food allergy.8. The method of claim 1 , wherein the food allergy comprises allergy to soy claim 1 , wheat claim 1 , eggs claim 1 , dairy claim 1 , peanuts claim 1 , tree nuts claim 1 , shellfish claim 1 , fish claim 1 , mushrooms claim 1 , stone fruits and other fruits.9. The method of claim 1 , wherein the agent is selected from the group consisting of: a small molecule claim 1 , a compound claim 1 , an antibody claim 1 , a peptide claim 1 , and an expression vector encoding RORγt.10. (canceled)11. The method of claim 9 , wherein the vector is a non-integrative vector selected from the group consisting of an episomal vector claim 9 , an EBNA1 vector claim 9 , a minicircle vector claim 9 , a non-integrative adenovirus claim 9 , a non-integrative ...

COMPOSITIONS AND METHODS FOR TREATING ALLERGIC INFLAMMATORY CONDITIONS

The invention provides methods of treating an allergic inflammatory condition characterized by inflammation of the squamous epithelium of a target tissue by reestablishing SPINK7 checkpoint control in the esophageal epithelium, and related compositions and methods. 1. A method of treating an allergic inflammatory condition in a subject in need thereof , the allergic inflammatory condition characterized by inflammation of a squamous epithelium in a target tissue of the subject , the method comprising administering to the subject a pharmaceutical composition comprising an amount of a therapeutic agent effective to replenish SPINK7 protein and/or SPINK7 anti-proteinase activity in the target tissue.2. The method of claim 1 , wherein the squamous epithelium is of esophageal tissue.3. The method of claim 2 , wherein the allergic inflammatory condition is esophageal eosinophilia (EE).4. The method of claim 3 , wherein the allergic inflammatory condition is eosinophilic esophagitis (EoE).5. The method of claim 1 , wherein the therapeutic agent is a serine proteinase inhibitor.6. The method of claim 5 , wherein the therapeutic agent is an alpha-1 proteinase inhibitor.7. The method of claim 6 , wherein the alpha-1 proteinase inhibitor is an alpha-1 antitrypsin inhibitor.8. The method of claim 1 , wherein the therapeutic agent is an inhibitor of urokinase plasminogen activator (uPA) or kallikrein 5 (KLK5) in the target tissue.9. The method of claim 8 , wherein the therapeutic agent is a proteinase inhibitor claim 8 , a KLK5-Fc fusion protein claim 8 , a KLK5 anti-sense polynucleotide claim 8 , a KLK5-directed miRNA claim 8 , a KLK5-directed shRNA claim 8 , or a KLK5-directed antibody.10. The method of claim 9 , wherein the therapeutic agent is selected from 3-(3-chlorophenyl)carboxy-7-hydroxymethyl courmarin or 3-carboxy-7-hydroxymethyl coumarin.11. The method of claim 1 , wherein the therapeutic agent comprises a recombinant mRNA encoding a SPINK7 protein claim 1 , or a ...

METHODS OF TREATING ALLERGY USING ANTI-BET V 1 ANTIBODIES

The present disclosure provides methods for treating, preventing, or ameliorating one or more symptoms of birch allergy or allergic disease in a subject by administering to the subject an antibody or antigen-binding fragment thereof that binds Bet v 1, or a cocktail of antibodies or antigen-binding fragments thereof that bind Bet v 1. 1. A method of treating birch allergy in a subject , the method comprising administering to the subject a pharmaceutical composition comprising:(a) a first anti-Bet v 1 antibody or antigen-binding fragment thereof, wherein the first anti-Bet v 1 antibody comprises a heavy chain complementarity determining region (HCDR) 1 comprising the amino acid sequence of SEQ ID NO:2, an HCDR2 comprising the amino acid sequence of SEQ ID NO:3, an HCDR3 comprising the amino acid sequence of SEQ ID NO:4, a light chain complementarity determining region (LCDR) 1 comprising the amino acid sequence of SEQ ID NO:6, an LCDR2 comprising the amino acid sequence of SEQ ID NO:7, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:8; and/or(b) a second anti-Bet v 1 antibody or antigen-binding fragment thereof, wherein the second anti-Bet v 1 antibody comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO:12, an HCDR2 comprising the amino acid sequence of SEQ ID NO:13, an HCDR3 comprising the amino acid sequence of SEQ ID NO:14, an LCDR1 comprising the amino acid sequence of SEQ ID NO:16, an LCDR2 comprising the amino acid sequence of SEQ ID NO:17, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:18; and/or(c) a third anti-Bet v 1 antibody or antigen-binding fragment thereof, wherein the third anti-Bet v 1 antibody comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO:22, an HCDR2 comprising the amino acid sequence of SEQ ID NO:23, an HCDR3 comprising the amino acid sequence of SEQ ID NO:24, an LCDR1 comprising the amino acid sequence of SEQ ID NO:26, an LCDR2 comprising the amino acid sequence of SEQ ID NO:27, and ...

Inflammatory Disease Treatment Composition Including Anti-Myosin Regulatory Light-Chain Polypeptide Antibody

Provided is a means for inhibiting a function of CD69, whereby allowing suppression of an inflammatory response. That is, provided are: a composition for treating an inflammatory disease which includes an antibody that specifically recognizes a myosin regulatory light chain polypeptide (hereinafter abbreviated as Myl), preferably Myl9, Myl12a, and Myl12b, and inhibits a result of an effect of coexistence of Myl with CD69; a method of treating an inflammatory disease, including administering, to a subject diagnosed as having an inflammatory disease, a therapeutically effective amount of the antibody; and a method of identifying a compound that inhibits a result of an effect of coexistence of Myl with CD69, and a method of identifying a candidate compound for treating an inflammatory disease, including selecting a compound that inhibits the result. 112-. (canceled)13. A method of treating an inflammatory disease , comprisingadministering, to a subject diagnosed as having an inflammatory disease, an antibody that specifically recognizes myosin regulatory light chain polypeptide (Myl) and inhibits a result of an effect of coexistence of Myl with CD69, in an amount effective in treating the inflammatory disease.14. The method of treating an inflammatory disease according to claim 13 , wherein the effect of coexistence of Myl with CD69 is a binding of Myl with CD69.15. The method of treating an inflammatory disease according to claim 13 , wherein the Myl is any one or more selected from the group consisting of Myl9 claim 13 , Myl12a claim 13 , and Myl12b.16. The method of treating an inflammatory disease according to claim 13 , wherein the antibody is an antibody that specifically recognizes a partial amino acid sequence of Myl9 claim 13 , Myl12a claim 13 , or Myl12b claim 13 , and the partial amino acid sequence is the amino acid sequence of SEQ ID NO: 24.17. The method of treating an inflammatory disease according to claim 13 , wherein the inflammatory disease is an ...

ANTIBODY FORMULATIONS

Formulations comprising an anti-IL-13 antibody are provided, including pharmaceutical formulations and methods of using such formulations. 160-. (canceled)61. A method of treating asthma in a patient comprising administering to the patient an effective amount of a formulation comprising an anti-IL13 antibody , wherein the concentration of antibody in the formulation is at least 100 mg/mL and the viscosity of the formulation is less than 15 centipoise (cP) at 25° C.62. The method of wherein the effective amount is 0.3 mL claim 61 , one mL or two mL or about 0.3 mL claim 61 , about one mL or about two mL.63. A method of treating idiopathic pulmonary fibrosis in a patient comprising administering to the patient an effective amount of a formulation comprising an anti-IL13 antibody claim 61 , wherein the concentration of antibody in the formulation is at least 100 mg/mL and the viscosity of the formulation is less than 15 centipoise (cP) at 25° C.64. The method of wherein the effective amount is 0.3 mL claim 63 , one mL or two mL or about 0.3 mL claim 63 , about one mL or about two mL.65. A method of administering subcutaneously a formulation comprising an anti-IL13 antibody claim 63 , the method comprising an article of manufacture comprising the formulation and a subcutaneous administration device claim 63 , wherein the concentration of antibody in the formulation is at least 100 mg/mL and the viscosity of the formulation is less than 15 centipoise (cP) at 25° C.66. (canceled)67. The method of claim 61 , wherein the formulation comprises a histidine acetate buffer claim 61 , pH 5.4 to 6.0 claim 61 , wherein the histidine acetate concentration in the buffer is between 5 mM and 40 mM.68. The method of claim 61 , wherein the formulation has extended stability.69. The method of claim 68 , wherein the formulation comprises 20 mM histidine acetate buffer claim 68 , pH 5.7 claim 68 , 175 mM sucrose claim 68 , and 0.03%>polysorbate 20 claim 68 , wherein the concentration of ...

Methods of Treating Inflammation

Methods for treating inflammation, including allergic inflammation, lymphocyte-driven inflammation, and inflammatory conditions such as allergic asthma and allergic lung inflammation, using inhibitors of the polycomb repressive complex 2 (PRC2) methyltransferase enhancer of zeste homolog 2 (Ezh2) are provided. 1. A method for preventing , reducing one or more symptoms of , or treating inflammation in a subject , comprising administering to the subject an inhibitor of the polycomb repressive complex 2 (PRC2) methyltransferase enhancer of zeste homolog 2 (Ezh2).2. The method according to claim 1 , wherein the inflammation is allergic inflammation.3. The method according to claim 1 , wherein the inflammation is lymphocyte-driven inflammation.4. The method according to claim 3 , wherein the inflammation is Th cell driven.5. The method according to claim 3 , wherein the lymphocyte-driven inflammation is chronic obstructive pulmonary disease (COPD) claim 3 , autoimmune disease or diabetes.6. The method according to claim 1 , wherein the inflammation is non-allergic asthma.7. The method according to claim 2 , wherein the allergic inflammation is any disorder which is initiated by an allergen.8. The method according to claim 2 , wherein the allergic inflammation is selected from the group consisting of allergic asthma claim 2 , atopic dermatitis claim 2 , allergic rhinitis (hay fever) claim 2 , urticaria (hives) claim 2 , food allergies claim 2 , drug allergies claim 2 , anaphylaxis and ocular allergic disorders.9. The method according to claim 1 , wherein the method reduces the effect of one or more symptoms of allergic inflammation selected from the group consisting of itchiness claim 1 , running nose claim 1 , sneezing claim 1 , watery eyes claim 1 , bronchoconstriction claim 1 , hives claim 1 , airway inflammation claim 1 , anaphylaxis claim 1 , and dermatitis.10. The method according to claim 1 , wherein the Ezh2 inhibitor is selected from the group consisting of ...

Agent for preventing and/or treating ocular inflammatory disease

The invention provides a method for prophylaxis and/or treatment of an ocular inflammatory disease comprising administering an effective amount of a pyrazolopyrimidine compound represented by formula (I), wherein R 1 represents —NR 1a R 1b (wherein R 1a and R 1b are the same or different and each represents a hydrogen atom and the like), and the like, R 2 represents the formula (R 2 −1) [wherein k and m represent each an integer of 0-2, n represents an integer of 0-2, L represents a single bond and the like, R 5 represents a halogen and the like, R 6 represents aryl and the like, X represents —CR 8 (wherein R 8 represents a hydrogen atom and the like), and the like, R 7 represents a hydrogen atom, and the like, and the like, R 3 represents —SO 2 R 13 (wherein R 13 represents lower alkoxy and the like), and the like, and R 4 represents a hydrogen atom and the like, or a pharmaceutically acceptable salt thereof.

Implanted Device

Disclosed is an implanted device, comprising a device base body and an active drug, wherein the device base body is pure zinc and/or a zinc alloy, the zinc content in the device base body is 0.1-100%, and the active drug comprises anti-allergic drugs. After the implantation of the implanted device into the human body, the surrounding tissues of the implant would not have a clear hypersensitive reaction due to the presence of the anti-allergic drugs, and the implanted device can be used to be implanted into the body for supporting organ chambers, to fill the hollow chambers of the organs and tissues or as orthopaedic implants etc. 1. An implanted device , comprising a device substrate and an active drug , wherein the device substrate is pure zinc and/or a zinc alloy; the device substrate contains 0.1 to 100 percent of zinc; and the active drug comprises an anti-allergic drug.2. The implanted device according to claim 1 , wherein the implanted device further comprises a zinc complexing agent; wherein the zinc complexing agent and the pure zinc or the zinc alloy in the device substrate form a complex in body fluid.3. The implanted device according to claim 2 , wherein the zinc complexing agent contains at least one coordination group; the coordination group is selected from the group consisting of hydroxyl on polycyclic aromatic hydrocarbon claim 2 , sulfydryl claim 2 , amino claim 2 , an aromatic heterocyclic group claim 2 , nitroso claim 2 , carbonyl claim 2 , sulpho claim 2 , a phosphate group and an organic phosphorus group; the hydroxyl on the polycyclic aromatic hydrocarbon is a phenolic hydroxyl; and the aromatic heterocyclic group is selected from the group consisting of furyl claim 2 , pyrryl claim 2 , imidazolyl claim 2 , triazolyl claim 2 , thienyl claim 2 , thiazolyl claim 2 , pyridyl claim 2 , a pyridone group claim 2 , pyranyl claim 2 , a pyrone group claim 2 , pyrimidyl claim 2 , pyridazinyl claim 2 , pyrazinyl claim 2 , quinolyl claim 2 , isoquinolyl ...

PURE HEPTASULFATED DISACCHARIDES HAVING IMPROVED ORAL BIOAVAILABILITY

Hypersulfated disaccharides with utility in asthma or asthma related disorders are disclosed. The heptasulfated disaccharides administered orally have comparable bioavailability to the intravenous administered dosage form. 2. The formulation according to wherein R-Ris selected from SOH.3. The formulation according to wherein the salt is a sodium salt.4. The formulation according to wherein said formulation is oral.5. The formulation according to which is i.v.6. The formulation according to in inhalable form.8. The method according to wherein the inflammatory condition is selected from pulmonary inflammation such as asthma and/or asthma related pathologies; pneumonia claim 7 , tuberculosis claim 7 , rheumatoid arthritis claim 7 , allergic reactions which impact the pulmonary system claim 7 , early and late phase responses in asthma and asthma related pathologies claim 7 , diseases of the small and large airways of the lung claim 7 , bronchospasm claim 7 , inflammation claim 7 , increased mucus production claim 7 , conditions which involve vasodilation claim 7 , plasma exudation claim 7 , recruitment of inflammatory cells such as neutrophils claim 7 , monocytes claim 7 , macrophages claim 7 , lymphocytes and eosinophils and/or release of inflammatory mediators by resident tissue cells (mast cells); conditions or symptoms which are caused by allergens claim 7 , secondary responses to infections claim 7 , industrial or occupational exposures claim 7 , ingestion of certain chemicals or foods claim 7 , drugs claim 7 , exercise or vasculitis; conditions or symptoms which involve acute airway inflammation claim 7 , prolonged airway hyperreactivity claim 7 , increases in bronchial hyperreactivity claim 7 , asthmatic exacerbations claim 7 , hyperresponsiveness; conditions or symptoms which involve the release of inflammatory mediators such as 15-HETE claim 7 , leukotriene C4 claim 7 , PAF claim 7 , cationic proteins or eosinophil peroxidases; conditions or symptoms which ...

METHODS AND COMPOSITIONS FOR ALLERGIC DISORDERS

The present invention relates to methods and compositions for treating, reducing, delaying, and/or preventing flares (e.g., recurrences, relapses) of allergic disorders with a biologic agent. 1. A method of preventing , reducing , and/or inhibiting an allergic disorder in a subject in need thereof , the method comprising administering to the subject a composition comprising a therapeutically effective amount of a biologic agent targeting an inflammatory mediator before and/or during an early phase of inflammation , with the proviso that the biologic agent is not an anti-IgE antibody.2. The method of claim 1 , wherein the subject is asymptomatic or paucisymptomatic with or without currently receiving and/or having received an anti-inflammatory agent claim 1 , an anti-allergy agent claim 1 , an immunomodulatory agent or a combination thereof3. The method of claim 2 , wherein the anti-inflammatory agent claim 2 , the anti-allergy agent claim 2 , and/or the immunomodulatory agent is selected from a glucocorticoid claim 2 , a non-steroidal anti-inflammatory agent claim 2 , a leukotriene antagonist claim 2 , a JAK inhibitor claim 2 , an immunoglobulin claim 2 , an anti-histamine claim 2 , allergen-specific immunotherapy agent claim 2 , non-specific immunotherapy agent claim 2 , and combinations thereof administered by either oral claim 2 , subcutaneous claim 2 , intramuscular claim 2 , intravenous and/or topical routes.4. The method of claim 1 , wherein the subject is a canine claim 1 , feline claim 1 , equine claim 1 , or human.5. The method of claim 4 , wherein the subject is a human.6. The method of claim 1 , wherein the inflammatory mediator is selected from histamine claim 1 , a leukotriene claim 1 , a prostaglandin claim 1 , a cytokine claim 1 , platelet activating factor (PAF) claim 1 , a growth factor claim 1 , a protease claim 1 , an immunoglobulin claim 1 , and combinations thereof.7. The method of claim 6 , wherein the inflammatory mediator is a cytokine ...

IMMUNE RESPONSE MODULATION USING LIVE BIOTHERAPEUTICS, FOR CONDITIONS SUCH AS ALLERGY DESENSITIZATION

Provided herein are compositions (e.g., probiotic, pharmaceutical, etc.) comprising one or more strains of non-Clostridia class bacteria and methods of use thereof for allergen desensitization. In particular, bacteria of bacterial classes such as Negativicutes, Actinobacteria, and Bacteroidia support allergen desensitization, for example, by promoting production of metabolites that aid in desensitization or performing catabolism of food allergens. 1Clostridium. A method of modulating an immune response in a subject , the method comprising administering a composition comprising non-clusters IV and XIVa bacteria to the subject.2. The method of claim 1 , wherein the modulation of the immune response comprises preventing allergen hypersensitivity or an inflammatory response.3. The method of claim 1 , wherein the modulation of the immune response comprises desensitizing a subject to an allergen or treating an allergen hypersensitivity or an inflammatory response.4. The method of claim 2 , wherein the subject is at risk of developing allergen hypersensitivity or an inflammatory condition.5. The method of claim 3 , wherein the subject suffers from hypersensitivity to an allergen or a chronic inflammatory condition.6. The method of claim 5 , wherein the subject suffers from hypersensitivity to one or more foods from the group consisting of milk claim 5 , milk proteins claim 5 , eggs claim 5 , fish claim 5 , shellfish claim 5 , hazelnuts claim 5 , walnuts claim 5 , almonds claim 5 , Brazil nuts claim 5 , peanuts claim 5 , shrimps claim 5 , mussels claim 5 , crab claim 5 , soy claim 5 , and wheat.7ClostridiumBacteroidetesFirmicutes.. The method of one of - claim 5 , wherein the non-clusters IV and XIVa bacteria comprises one or more species selected from the phyla Actinobacteria claim 5 , claim 5 , and8Clostridium. The method of claim 7 , wherein the non-clusters IV and XIVa bacteria comprises one or more species selected from the phylum Actinobacteria and genus ...

Finished Fibrous Structures and Methods of Their Use and Preparation

The disclosure is directed to fibrous structures finished with active pharmaceutical ingredients, as well as methods of their manufacturer and use. 1. A mechanically dewatered , finished , non-occlusive , pharmaceutical fibrous structure comprising natural fibers , manmade fibers , synthetic fibers , or a mixture thereof ,wherein the fibrous structure has been finished with a finishing composition that is a homogeneous dispersion comprising an active pharmaceutical ingredient or a pharmaceutically acceptable salt thereof, a solvent and a surfactant;wherein the fibrous structure is finished by being caused to interact with the homogeneous dispersion by at least one of diffusion of the homogeneous dispersion into the fibrous structure's fibers, deposition of the homogeneous dispersion onto the surfaces of the fibrous structure's fibers, and deposition of the homogeneous dispersion onto the interstices between the fibrous structure's fibers; andwherein the dry weight of the mechanically dewatered, finished, non-occlusive, pharmaceutical fibrous structure is increased at least about 20% Add-on, as compared to the dry weight of the fibrous structure absent the finishing treatment.2. The mechanically dewatered claim 1 , finished claim 1 , non-occlusive claim 1 , pharmaceutical fibrous structure of claim 1 , wherein following application to the intact skin of a subject claim 1 , the mechanically dewatered claim 1 , finished claim 1 , non-occlusive claim 1 , pharmaceutical fibrous structure provides locally claim 1 , systemically or both locally and systemically claim 1 , therapeutically effective amounts of the active ingredient to the subject.3. The mechanically dewatered claim 1 , finished claim 1 , non-occlusive claim 1 , pharmaceutical fibrous structure of claim 1 , wherein the finishing composition comprises the surfactant in an amount of from about 0.1% (w/w) to about 5% (w/w).4. The mechanically dewatered claim 1 , finished claim 1 , non-occlusive claim 1 , ...

Composition for the treatment of type i allergic hypersensitivities by immune desensitization through slit immunotherapy with unadulterated allergen, vitamin a, vitamin d and an immuno-effective amount of adjuvant of essential oils

In one embodiment, the invention provides a composition that includes therapeutically effective amount of any unadulterated pollen listed in FIG. 1. The invention is comprised of specific mass(es) of the unadulterated pollen composition of one or multiple pollens per daily dose, a range of mass of vitamin A, a range of mass of vitamin D, and an immune-effective amount of an adjuvant comprised of one or more of the essential oils Eucalyptol, Thymus, Oregano, Bergamot, Fennel, Tea Tree, Peppermint, Fennel, Cinnamon and Clove. The duration of the therapeutically effective amount of unadulterated pollen will preferably be administered 0-52 weeks prior to exposure to the allergen and for a period of 6-8 weeks. It could also be administered as a maintenance treatment during the allergic exposure and for multiple years. In some embodiments, the invention provides a method for treating allergies.

Suppression of allergic lung inflammation and hyperreactivity

This disclosure compositions and methods for the treatment and prevention of allergic inflammation and diseases associated with such, e.g., asthma.

Human antibodies and proteins

The present invention provides composite proteins, including antibodies, which show reduced immunogenicity. In particular, composite antibodies for use in humans are provided, in particular antibodies which have been modified to remove one or more T-cell epitopes. Methods for generating such proteins are also provided.

Human antibodies and proteins

The present invention provides composite proteins, including antibodies, which show reduced immunogenicity. In particular, composite antibodies for use in humans are provided, in particular antibodies which have been modified to remove one or more T-cell epitopes. Methods for generating such proteins are also provided.

Barn dust extract for the prevention and treatment of diseases

The present invention relates to a method of preparing a barn dust extract, said barn dust extract, and a composition comprising said barn dust extract. The barn dust extract is useful in the prevention or treatment of a disease.

Topically applicable pharmaceutical preparation

A topical pharmaceutical preparation for administering a slightly soluble PDE4 inhibitor is described. A surprisingly good systemic bioavailability is observed with this dosage form.

TREATMENT OF ALLERGIC RHINITIS USING A COMBINATION OF MOMETASONE AND OLOPATADINE

The present invention relates to a method of treating allergic rhinitis in a subject (e.g., a pediatric human subject) in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its salt. 1. A method of treating symptoms associated with allergic rhinitis in a pediatric human subject in need thereof comprising nasally administering twice daily , one spray per nostril of a fixed-dose pharmaceutical composition comprising mometasone furoate and olopatadine hydrochloride , wherein each spray comprises about 25 mcg of mometasone furoate and about 665 mcg olopatadine hydrochloride.2. (canceled)3. The method of claim 1 , wherein the symptoms are selected from nasal symptoms.4. The method of claim 3 , wherein the nasal symptoms are selected from nasal congestion claim 3 , rhinorrhea claim 3 , itching and sneezing.5. The method of claim 1 , wherein the human subject is 2 to under 12 years of age.6. The method of claim 1 , wherein the human subject is 2 to under 6 years of age.7. The method of claim 1 , wherein the human subject is 6 to under 12 years of age.8. The method of claim 1 , wherein the allergic rhinitis is selected from seasonal allergic rhinitis claim 1 , perennial allergic rhinitis claim 1 , and persistent allergic rhinitis.9. The method of claim 8 , wherein the allergic rhinitis is seasonal allergic rhinitis.10. The method of claim 8 , wherein the allergic rhinitis is perennial allergic rhinitis.11. The method of wherein the administration of the pharmaceutical composition provides relief from one or more symptoms of allergic rhinitis within 15 minutes of administration.12. The method of claim 1 , wherein the administration of the pharmaceutical composition provides relief from one or more symptoms of allergic rhinitis within 10 minutes of administration.13. A method of treating symptoms associated with allergic rhinitis in a pediatric human ...

AQUEOUS COMPOSITION FOR EYE DROPS AND NASAL DROPS

Provided is an aqueous composition for ophthalmic or nasal administration comprising levocetirizine or its salt. In one embodiment, the composition comprises levocetirizine or its salt at a levocetirizine concentration of 0.05-0.5% (w/v). The composition may further comprise a surface active agent and/or an organic acid salt. 1. An aqueous composition for ophthalmic or nasal administration , which comprises levocetirizine or its salt as an active ingredient.2. The composition according to claim 1 , wherein the concentration of levocetirizine or its salt in the composition as the levocetirizine concentration is 0.05-0.5% (w/v).3. The composition according to claim 1 , which further comprises a surface active agent and/or an organic acid salt.4. The composition according to claim 3 , which comprises polysorbate 80 as a surface active agent.5. The composition according to claim 4 , wherein the concentration of the surface active agent in the composition is 0.1-2.0% (w/v).6. The composition according to claim 3 , wherein the composition comprises a citric acid salt as an organic acid salt.7. The composition according to claim 3 , wherein the concentration of the organic acid salt in the composition is 0.4-2.5% (w/v).8. The composition according to claim 1 , which further comprises polyhexanide hydrochloride as a preservative.9. The composition according to claim 1 , which comprises 0.05-0.5% (w/v) as levocetirizine concentration of levocetirizine or its salt claim 1 , about 0.1-2.0% (w/v) of polysorbate 80 claim 1 , about 0.4-2.5% (v/w) of citric acid salt claim 1 , about 0.001-0.3% (w/v) of disodium edetate claim 1 , and polyhexanide hydrochloride.10. The composition according to claim 9 , which comprises 0.05-0.5% (w/v) as levocetirizine concentration of levocetirizine or its salt claim 9 , about 0.2% (w/v) of polysorbate 80 claim 9 , about 0.75% (v/w) of sodium citrate claim 9 , about 0.018% (w/v) of disodium edetate claim 9 , and 0.00005-0.0005% (w/v) of ...

Treatments of ocular allergy with alcaftadine

Compositions, kits and methods for the treatment or prevention of ocular allergies and inflammation and the symptoms thereof comprising alcaftadine or a pharmaceutically acceptable salt thereof.

Methods for treating or preventing asthma by administering an il-4r antagonist

Methods for treating or preventing asthma (e.g., allergic asthma, asthma associated with allergic bronchopulmonary aspergillosis (ABPA), moderate-to-severe asthma, persistent asthma or the like) and associated conditions (e.g., ABPA, ABPA comorbid with asthma, ABPA comorbid with cystic fibrosis (CF), ABPA comorbid with asthma and CF) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

Compositions and methods for the treatment of allergy

Provided herein are compositions and methods for the treatment of allergy, such as food allergy. Also provided herein are compositions and methods for modulating an immune response associated with allergy and/or inducing immune tolerance or desensitization to an allergy, such as a food allergy.

Gastrointestinal release capsule for use in a method for desensitising and/or inducing tolerance in a patient with a peanut allergy

Gastro-intestinal release capsule intended for oral use in a method for desensitizing and/or inducing tolerance in a peanut-allergic subject or, alternatively, for diagnosing a peanut allergy in a subject. The capsule has a shell and a core, the core has a composition of peanut including peanut, at least one oil, at least one first pulverulent excipient and, optionally, at least one second prebiotic excipient. The capsule is provided and ingested in an unopened form.

METHOD OF TREATING AN ALLERGY WITH ALLERGEN-SPECIFIC MONOCLONAL ANTIBODIES

The present invention provides methods for treating an allergy by administering one or more antibodies that bind specifically to the allergen. In certain embodiments, the antibodies useful for treating an allergen, bind specifically to the cat allergen, Fel d1. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Fel d1. The antibodies of the invention are useful for binding to the Fel d1 allergen in vivo, thus preventing binding of the Fel d1 allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and/or basophils, thus ameliorating the untoward response to the cat allergen in sensitized individuals.

A STERICALLY STABILIZED CARRIER FOR SUBCUTANEOUS, SUBLINGUAL, AND ORAL THERAPEUTICS, COMPOSITIONS AND METHODS FOR TREATING A MAMMAL

Disclosed herein are pharmaceutical compositions and methods for oral, sublingual or subcutaneous administration comprising a sterically stabilized liposome carrier comprising: i) poly (ethylene glycol) distearoylphosphatidylethanolamine (PEG-DSPE); and ii) at least one of phosphatidylglycerol and phosphatidylcholine. Compositions and methods for treatment of food allergy and eosinophilic esophagitis are also described. 1. A method for treating eosinophilic esophagitis (EoE) , comprising: administering to a subject in need thereof , a pharmaceutical composition comprising a therapeutically effective amount of at least one agent suitable for treating eosinophilic esophagitis , wherein the at least one agent is encapsulated in a liposome carrier.2. The method of claim 1 , wherein the liposome carrier comprises phosphatidylglycerol (PG) claim 1 , phosphatidylcholine (PC) claim 1 , phosphatidylethanolamine (PE) claim 1 , phosphatidylserine (PS) claim 1 , phosphatidylinositol (PI) claim 1 , or any combination or derivative thereof.3. The method of or claim 1 , wherein the liposome carrier is a sterically stabilized liposome carrier.4. The method of claim 3 , wherein the sterically stabilized liposome carrier comprises poly (ethylene glycol) distearoylphosphatidylethanolamine (PEG-DSPE) claim 3 , PEG-dipalmitoylphosphatidylethanolamine (DPPE) claim 3 , PEG-di-C:15 PE claim 3 , PEG-soy PE claim 3 , or PEG-egg PE.5. The method of any one of - claim 3 , wherein the administering is performed subcutaneously claim 3 , sublingually claim 3 , intranasally claim 3 , or orally.6. The method of any one of - claim 3 , wherein the at least one agent comprises a proton-pump inhibitor (PPI) claim 3 , a corticosteroid claim 3 , or any combination claim 3 , or derivative thereof.7. The method of claim 6 , wherein the proton-pump inhibitor comprises omeprazole claim 6 , lansoprazole claim 6 , dexlansoprazole claim 6 , esomeprazole claim 6 , pantoprazole claim 6 , rabeprazole claim 6 , ...

Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance

The invention provides methods, compositions, and kits containing phentolamine for improving visual performance. In particular, the invention provides improvement in visual performance, such as improvement in visual acuity, by daily ophthalmic administration of a phentolamine solution to an eye of a patient at or near the bedtime of the patient for an extended duration while minimizing the occurrence of adverse side effects, such as eye redness during the patient's waking hours.

Medicinal preparation and medical instrument

An object is to provide a pharmaceutical preparation for preventing or treating allergic conjunctivitis which is to be administered to the intranasal mucosa. Provided is a pharmaceutical preparation for preventing or treating allergic conjunctivitis which is to be administered to the intranasal mucosa, the pharmaceutical preparation including a composite particle containing one or more titanium oxide particles, one or more metal particles, and one or more calcium phosphate particles. Also provided is a medical device for preventing or treating allergic conjunctivitis, the medical device including an breathable mask portion covering the nasal cavity of a subject in need of prevention or treatment of allergic conjunctivitis, ear loop portions provided on the breathable mask portion, and a composite particle releasably attached to the breathable mask portion, the composite particle containing one or more titanium oxide particles, one or more metal particles, and one or more calcium phosphate particles.

METHODS OF USE AND PHARMACEUTICAL COMPOSITIONS OF A SELECTIVE SYK INHIBITOR

Provided herein are methods of using Syk inhibitors, such as a selective Syk inhibitor, Compound 1 or a pharmaceutically acceptable salt thereof, in treating allergic and/or inflammatory diseases or conditions of the eye. Also provided is pharmaceutical compositions, in particular eyedrop ophthalmic compositions, comprising Compound 1 or a pharmaceutically acceptable salt thereof, useful in the methods. 2. An ophthalmic composition comprising about 0.01% w/w to about 10% w/w of Compound 1 or a pharmaceutically acceptable salt thereof , a tonicity modifier , a buffer and water.3. An ophthalmic composition comprising about 0.1% w/w to about 1% w/w of Compound 1 or a pharmaceutically acceptable salt thereof , a tonicity modifier , a buffer and water.4. The ophthalmic composition of any one of - , comprising Compound 1 HCl salt.5. The ophthalmic composition of any one of - , comprising about 0.1% to about 5% of a tonicity modifier , about 0.005 to about 0.02% w/w of a preservative , and a buffer , and having a pH of about 5.5 to 7.6. The ophthalmic composition of any one of - , comprising about 0.2% to about 2% w/w of a tonicity modifier , about 0.005 to about 0.02% w/w of a preservative , and a buffer , and having a pH of about 6.7. The ophthalmic composition of any one of - , comprising about 0.5% to about 1.5% w/w of a tonicity modifier , about 0.01% w/w of a preservative , and a buffer , and having a pH of about 6.8. The ophthalmic composition of any one of - , wherein the tonicity modifier is one or more of glycerin , NaCl , and KCl.9. The ophthalmic composition of any one of - , wherein the tonicity modifier is glycerin.10. The ophthalmic composition of any one of - , wherein the preservative is benzalkonium chloride.11. The ophthalmic composition of any one of - , wherein the buffer is a phosphate buffer.12. The ophthalmic composition of any one of - , wherein the buffer is a citrate buffer.13. An ophthalmic composition comprising about 0.01% to about 1% w/w ...

Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season

The present invention relates to mucosal allergen-specific immunotherapy with a seasonal allergen, wherein the therapy is initiated after start of the pollen season of the seasonal allergen. Preferably, the seasonal allergen is provided in solid dosage form and is administered daily. Furthermore, advantageously, the same dose may be used throughout the treatment period since up-dosing is not required.

Novel chalcone derivatives having an anti-allergic activity

The present invention relates to the compounds of formula (I): wherein: R 2 , R 4 and R 6 , either identical or different, represent a hydrogen, chlorine bromine, iodine or fluorine atom, or a group —OH or —O-alkyl comprising from 1 to 6 carbon atoms; R 2 ′ and R 4 ′, either identical or different, represent a hydrogen atom, or a group —OH or —O-alkyl comprising from 1 to 6 carbon atoms; with R 2 ′ and/or R 4 ′ which represent a methoxy group; n is equal to 1, 2, 3; X═CH 2 , O, S or N(R 7 ); and R 7 represents a hydrogen atom or an alkyl group comprising from 1 to 6 carbon atoms; as well as pharmaceutically acceptable hydrates, solvates and salts thereof.

RNAi-MEDIATED INHIBITION OF HISTAMINE RECEPTOR H1-RELATED CONDITIONS

RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.

Human antibodies to bet v 1 and methods of use thereof

Provided herein are antibodies that bind Fagales allergens, Fagales related allergens, birch pollen, or Bet v 1, compositions comprising the antibodies, nucleic acids encoding the antibodies, and methods of using the antibodies. According to certain embodiments, the antibodies are fully human monoclonal antibodies that bind to Bet v 1. The antibodies are useful for binding Bet v 1 in vivo, thus preventing binding of the allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and/or basophils, thus ameliorating the untoward response to the Fagales allergens in sensitized individuals.

Isoxazolidine derivatives

Anti-inflammatory and antiallergic compounds of the glucocorticosteroid series, according to formula (I) according to formula (I) defined herein are useful for treating diseases of the respiratory tract characterized by airway obstruction.

4-pregenen-11beta-17-21-triol-3,20-dione derivatives

The present invention relates to novel 4-pregenen-11β-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation.

Phosphoric Acid Ester Derivatives

To provide a novel compound that has S1P lyase inhibitory ability and induces a reduction in the number of lymphocytes, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the compound or pharmaceutically acceptable salt thereof as an active ingredient. A compound represented by the general formula (I): or a pharmaceutically acceptable salt thereof.

Rapid clearance of antigen complexes using novel antibodies

The present invention relates to rapid clearance molecules that bind target antigens and FcγRIIb with increased affinity as compared to parent molecules, said compositions being capable of causing accelerated clearance of such antigens. Such compositions are useful for treating a variety of disorders, including allergic diseases, atherosclerosis, and a variety of other conditions.

PEANUT ORAL IMMUNOTHERAPY WITH MAINTENANCE DOSE

The present disclosure relates to improved oral immunotherapy methods for treating peanut allergy. The disclosure provides methods for treating a subject for a peanut allergy by an oral immunotherapy comprising an up-dosing phase and a maintenance phase. In certain embodiments, the methods comprise non-daily administration to the subject of a maintenance phase dose. In certain embodiments, the methods comprise administering a maintenance phase dose for more than 24 weeks. In other embodiments, the disclosure provides methods for reducing the risk of an allergic adverse event in a subject receiving an oral immunotherapy dosage therapy. 1. A method of treating a subject for a peanut allergy by an oral immunotherapy comprising an up-dosing phase and a maintenance phase , the method comprising administering to the subject on a non-daily basis a maintenance phase dose during at least a portion of the maintenance phase.224-. (canceled)25. A method of treating a subject for a peanut allergy by an oral immunotherapy , comprising administering to the subject peanut protein according to an oral immunotherapy schedule comprising an up-dosing phase and a maintenance phase , the maintenance phase comprising administering to the subject a maintenance phase dose for more than 24 weeks.26. The method of claim 25 , wherein the maintenance phase dose is administered on a daily basis for at least a portion of the maintenance phase.27. The method of claim 25 , wherein the maintenance phase dose is administered to the subject for about 28 weeks or more.28. The method of claim 25 , wherein the maintenance phase dose is administered to the subject for about 52 weeks or more.29. The method of claim 25 , wherein the maintenance phase dose is administered to the subject for about 52 weeks to about 108 weeks.30. The method of claim 25 , wherein the subject does not tolerate a dose of about 1000 mg peanut protein after 24 weeks of the maintenance phase.31. The method of claim 25 , wherein the ...

DIETARY BUTYRATE FOR TREATING OR PREVENTING AN ALLERGIC DISORDER

A compound having the formula or combinations thereof, for use in the treatment or prevention of an allergic disorder, wherein R, R, R, R, Rand Rare independently, a long chain fatty acid having between 16 and 20 carbons. 3. A method according to claim 2 , wherein the composition comprises the compound having formula (1) claim 2 , the compound having formula (2) claim 2 , the compound having formula (3) and the compound having formula (4).4. A method according to claim 2 , wherein the compounds having formula (1) claim 2 , (2) claim 2 , (3) and (4) claim 2 , comprise at least 50% by weight of the total triglycerides of the composition.5. A method according to claim 1 , comprising the compound having the formula (4) as the main butyrate moiety containing triglyceride in the composition claim 1 , wherein the compound of formula (4) provides at least 20% by weight of the butyrate moiety containing triglycerides in the composition.6. A method according to claim 2 , wherein the compounds having formula (1) claim 2 , (2) claim 2 , (3) and (4) claim 2 , comprise at least 50% by weight of the total butyrate moiety containing triglycerides in the composition.7. A method according to claim 2 , wherein tributyrin comprises less than 10% by weight of the total triglycerides in the composition.8. A method according to claim 2 , wherein the composition further comprises vitamin A and/or dietary fiber.9. A method according to claim 2 , wherein the composition is a nutritional composition.10. A method according to claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , R claim 1 , Rand/or Ris an unsaturated fatty acid.11. A method according to claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , R claim 1 , Rand/or Ris selected from the group consisting of oleic acid claim 1 , palmitic acid claim 1 , and linoleic acid.12. A method according to claim 1 , wherein the allergic disorder is selected from one or more of the group consisting of: a food allergy claim 1 , a food intolerance ...

EXTRACELLULAR DOMAIN OF ALPHA SUBUNIT OF IGE FC RECEPTOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME AND METHOD FOR PRODUCING SAME

The present invention provides a polypeptide dimeric protein containing two monomers, each of which contains an extracellular domain (FcεRIa-ECD) of an alpha subunit of an IgE Fc receptor. The dimeric protein according to the present invention has advantages that an excellent binding ability to IgE is exhibited as compared with a conventional therapeutic agent containing an anti-IgE antibody, and less other side effects are exhibited due to lack of ADCC and CDC functions. Thus, the dimeric protein can be applied to a medical product for treating or preventing an IgE-mediated allergic disease. 1. A polypeptide dimer , comprising:two monomers, each of which contains an extracellular domain (FcεRIα-ECD) of an alpha subunit of an IgE Fc receptor,wherein the monomer contains a modified Fc region, andthe modified Fc region and the FcεRIα-ECD are linked via a hinge.2. The polypeptide dimer of claim 1 ,wherein the extracellular domain of the alpha subunit of the IgE Fc receptor is the amino acid sequence of SEQ ID NO: 1 or a fragment thereof.3. The polypeptide dimer of claim 1 ,wherein the modified Fc region is SEQ ID NO: 2.4. The polypeptide dimer of claim 1 ,wherein the hinge is a hinge region derived from immunoglobulin IgD or a variant thereof.5. The polypeptide dimer of claim 4 ,wherein the hinge region or variant thereof derived from immunoglobulin IgD contains at least one cysteine.8. The polypeptide dimer of claim 1 ,wherein the hinge has any one amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 19.9. A polynucleotide that encodes the monomer according to which contains an extracellular domain (FcεRIα-ECD) of an alpha subunit of an IgE Fc receptor.10. An expression vector claim 9 , loaded with the polynucleotide according to .11. A host cell claim 10 , into which the expression vector according to is introduced.12. A pharmaceutical composition for treating or preventing an allergic disease claim 1 , comprising claim ...

High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions

The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) for treatment of pulmonary conditions (e.g. asthma). The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

Method for preparing gos-preparation with beta-galactosidase from cryptococcus terrestris, gos preparations obtainable thereby and uses thereof

The invention relates to the field of nutritional ingredients, in particular to economically attractive methods for producing hypoallergenic galactooligosaccharides (HA-GOS) and the use thereof in food and feed items. Provided is a method for the production of a HA-GOS preparation, comprising contacting a lactose feed with a beta-galactosidase (EC 3.2.1.23) comprising an amino acid sequence according to any of SEQ ID NO: 1, 2, 3 or 4, or an amino acid sequence that is at least 80% identical thereto, wherein the lactose feed is a cheese whey permeate (CWP) or a CWP that is enriched in sialyllactose (SL-CWP).

Sublingual Epinephrine Tablets

The present disclosure provides sublingual epinephrine tablets and methods of treating anaphylaxis, methods for concomitant therapy during a cardiac event, treating hypoglycemia, and prophylaxis for immunotherapy, using sublingual epinephrine tablets. 1. A sublingual epinephrine tablet comprising: epinephrine bitartrate and at least one of citric acid , mannitol , avicel , ludiflash , croscarmellose and magnesium stearate.2. The sublingual epinephrine tablet of claim 1 , wherein the epinephrine tablet disintegrates in water between 15 to 80 seconds.3. The sublingual epinephrine tablet of claim 1 , wherein the amount of epinephrine dissolved in water after 120 seconds is between 73.6 and 97.9% of the epinephrine in the tablet.4. The sublingual epinephrine tablet of claim 1 , wherein the amount of epinephrine dissolved in water after 15 minutes is between 79.3 and 95.9% of the epinephrine in the tablet.5. The sublingual epinephrine tablet of claim 1 , wherein the amount of epinephrine dissolved in water after 30 minutes is between 83.1 and 97.4% of the epinephrine in the tablet.6. The sublingual epinephrine tablet of claim 1 , wherein the amount of epinephrine dissolved in water after 45 minutes is between 84.4 and 100% of the epinephrine in the tablet.7. The sublingual epinephrine tablet of claim 1 , wherein the amount of epinephrine dissolved in water after 60 minutes is between 86.4 and 100% of the epinephrine in the tablet.8. A method of treating anaphylaxis in a subject comprising administering to the subject a sublingual tablet comprising epinephrine and at least one of citric acid claim 1 , mannitol claim 1 , avicel claim 1 , ludiflash claim 1 , croscarmellose and magnesium stearate claim 1 , wherein the subject is experiencing anaphylaxis.9. The method of claim 8 , wherein the subject is experiencing anaphylaxis and is experiencing hypotension.10. A method of increasing an amount of epinephrine absorbed by a subject comprising administering a sublingual tablet ...

BIARYL PIPERIDINE AMIDE COMPOUNDS AND METHODS OF USE THEREOF

The present application is directed to biaryl piperidine amide compounds, or pharmaceutically acceptable salts, solvates, and prodrugs thereof, and methods of use thereof. 114.-. (canceled)17. The method of further comprising modulating subsequent biochemical pathways culminating in cellular activation.18. The method of further comprising modulating production of a responsive cytokine.19. The method of claim 16 , wherein the antigen receptor is a T cell receptor.20. (canceled)25. The method according to claim 15 , wherein Ris selected from hydrogen claim 15 , halogen claim 15 , C-Calkyl claim 15 , C-Chaloalkyl claim 15 , OH claim 15 , O(C-Calkyl) claim 15 , OCF claim 15 , OCFH claim 15 , OCFH claim 15 , CN claim 15 , N claim 15 , NO claim 15 , NH claim 15 , NH(C-Calkyl) claim 15 , and N(C-Calkyl).26. The method according to claim 25 , wherein Ris selected from hydrogen claim 25 , halogen claim 25 , and CN.27. The method according to claim 15 , wherein Ris selected from hydrogen claim 15 , halogen claim 15 , C-Calkyl claim 15 , C-Chaloalkyl claim 15 , OH claim 15 , O(C-Calkyl) claim 15 , OCF claim 15 , OCFH claim 15 , OCFH claim 15 , CN claim 15 , NH claim 15 , NH(C-Calkyl) claim 15 , and N(C-Calkyl).28. The method according to claim 27 , wherein Ris selected from hydrogen claim 27 , halogen claim 27 , C-Calkyl claim 27 , OH claim 27 , and O(C-Calkyl).29. The method according to claim 15 , wherein Ris selected from hydrogen claim 15 , halogen claim 15 , C-Calkyl claim 15 , C-Chaloalkyl claim 15 , OH claim 15 , O(C-Calkyl) claim 15 , OCF claim 15 , OCFH claim 15 , OCFH claim 15 , CN claim 15 , NH claim 15 , NH(C-Calkyl) claim 15 , N(C-Calkyl) claim 15 , S(O)NRR claim 15 , C(O)NRR claim 15 , COR claim 15 , and COOR.30. The method according to claim 29 , wherein Ris selected from hydrogen claim 29 , halogen claim 29 , C-Calkyl claim 29 , C-Chaloalkyl claim 29 , OH claim 29 , O(C-Calkyl) claim 29 , CN claim 29 , S(O)NRR claim 29 , C(O)NRR claim 29 , COR claim 29 , and ...

TREATMENT OF ALLERGIC RHINITIS USING A COMBINATION OF MOMETASONE AND OLOPATADINE

The present invention relates to a method of treating allergic rhinitis in a subject (e.g., a pediatric human subject) in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its salt. 1. A method of treating symptoms associated with allergic rhinitis in a human subject in need thereof comprising nasally administering twice daily , one or two sprays per nostril of a fixed-dose pharmaceutical composition comprising mometasone furoate and olopatadine hydrochloride , wherein each spray comprises about 25 mcg of mometasone furoate and about 665 mcg olopatadine hydrochloride.2. (canceled)3. The method of claim 1 , wherein the symptoms are selected from nasal symptoms.4. The method of claim 3 , wherein the nasal symptoms are selected from nasal congestion claim 3 , rhinorrhea claim 3 , itching and sneezing.5. The method of claim 1 , wherein the human subject is 2 to under 12 years of age.6. The method of claim 1 , wherein the human subject is 2 to under 6 years of age.7. The method of claim 1 , wherein the human subject is 6 to under 12 years of age.8. The method of claim 1 , wherein the allergic rhinitis is selected from seasonal allergic rhinitis claim 1 , perennial allergic rhinitis claim 1 , and persistent allergic rhinitis.9. The method of claim 8 , wherein the allergic rhinitis is seasonal allergic rhinitis.10. The method of claim 8 , wherein the allergic rhinitis is perennial allergic rhinitis.11. The method of claim 1 , wherein the administration of the pharmaceutical composition provides relief from one or more symptoms of allergic rhinitis within 15 minutes of administration.12. The method of claim 1 , wherein the administration of the pharmaceutical composition provides relief from one or more symptoms of allergic rhinitis within 10 minutes of administration.1325-. (canceled)26. A method of treating a human subject suffering from allergic ...

ANTI-STEM CELL FACTOR ANTIBODIES AND METHODS OF USE THEREOF

The disclosure relates to antibodies and antigen-binding fragments thereof that bind to Stem Cell Factor (SCF). The antibodies and antigen-binding fragments thereof specifically bind to SCF248. The disclosure further relates to methods for making the antibodies, and to methods of use of the antibodies including methods of treatment for inflammatory and/or fibrotic diseases and disorders. 1. An antibody or fragment thereof that specifically binds to stem cell factor (SCF) , wherein the antibody comprises a heavy chain CDR1 , CDR2 , and CDR3 comprising SEQ ID NOs: 1 , 2 , and 3 , respectively.2. The antibody or fragment thereof of claim 1 , wherein the antibody further comprises a light chain CDR1 claim 1 , CDR2 claim 1 , and CDR3 comprising SEQ ID NOs: 4 claim 1 , 5 claim 1 , and 6 claim 1 , respectively.3. The antibody or fragment thereof of or claim 1 , wherein the antibody comprises a heavy chain variable region having at least 80% identity to a sequence selected from SEQ ID NOs: 7 claim 1 , 8 claim 1 , 9 claim 1 , 10 claim 1 , and 11.4. The antibody or fragment thereof of claim 3 , wherein the antibody comprises a heavy chain variable region having at least 90% identity to a sequence selected from SEQ ID NOs: 7 claim 3 , 8 claim 3 , 9 claim 3 , 10 claim 3 , and 11.5. The antibody or fragment thereof of or claim 3 , wherein the antibody comprises a light chain variable region having at least 80% identity to a sequence selected from SEQ ID NOs: 13 claim 3 , 14 claim 3 , 15 claim 3 , and 16.6. The antibody or fragment thereof of claim 5 , wherein the antibody comprises a light chain variable region having at least 90% identity to a sequence selected from SEQ ID NOs: 13 claim 5 , 14 claim 5 , 15 claim 5 , and 16.7. The antibody or fragment thereof of claim 1 , wherein the antibody or fragment thereof comprises a heavy chain variable region amino acid sequence selected from SEQ ID NOs: 7 claim 1 , 8 claim 1 , 9 claim 1 , 10 claim 1 , and 11; and a light chain variable ...

ANTIBODY FOR BINDING TO INTERLEUKIN 4 RECEPTOR

Disclosed is an antibody capable of binding to the interleukin 4 (IL-4) receptor (IL-4). Also disclosed are a nucleic acid sequence encoding the antibody, a vector including the nucleic acid sequence, and a host cell transformed or transfected with the vector. Provided are a method for producing the antibody, a medical use of the antibody, and a kit including the antibody. 110-. (canceled)11. An isolated nucleic acid or set of nucleic acids encoding an isolated anti-interleukin 4 receptor (IL-4R) antibody comprising a variable heavy (VH) chain sequence comprising three heavy chain CDR sequences , CDR-H1 , CDR-H2 , and CDR-H3 , and a variable light (VL) chain sequence comprising three light chain CDR sequences , CDR-L1 , CDR-L2 , and CDR-L3 , wherein the isolated antibody exhibits a 2-fold higher area under the drug-time curve as compared to a control antibody comprising a light chain variable region sequence as set forth in SEQ ID NO: 58 and a heavy chain variable region sequence as set forth in SEQ ID NO: 93.12. A vector comprising the isolated nucleic acid or set of nucleic acids of .13. A host cell comprising the isolated nucleic acid or set of nucleic acids of .14. A method of producing an isolated antibody which binds to IL-4R claim 13 , comprising expressing the isolated antibody with the host cell of and isolating the expressed antibody.15. A method of preventing claim 13 , treating claim 13 , or ameliorating inflammation or allergic disease in a subject in need thereof claim 13 , comprising administering to the subject an isolated anti-IL-4R antibody comprising a variable heavy (VH) chain sequence comprising three heavy chain CDR sequences claim 13 , CDR-H1 claim 13 , CDR-H2 claim 13 , and CDR-H3 claim 13 , and a variable light (VL) chain sequence comprising three light chain CDR sequences claim 13 , CDR-L1 claim 13 , CDR-L2 claim 13 , and CDR-L3 claim 13 , wherein the isolated antibody exhibits at least a 2-fold higher area under the drug-time curve as ...

SOYBEAN ALLERGY ANTIGEN

The present invention provides novel antigens of an allergy to soybean, methods and kits for diagnosing an allergy to soybean, pharmaceutical compositions comprising such an antigen, soybeans or processed products of soybean in which such an antigen is eliminated, and a tester for determining the presence or absence of a soybean antigen in an object of interest. 1. A kit for diagnosing an allergy to a soybean , the kit comprising , as an antigen , at least one of proteins defined below in any of the following (1) to (8): (1A-a) a protein comprising an amino acid sequence with deletion, substitution, insertion or addition of one or several amino acids in SEQ ID NO: 2;', '(1A-b) a protein comprising an amino acid sequence having at least 70% identity to the amino acid sequence of SEQ ID NO: 2;', '(1A-c) a protein comprising an amino acid sequence encoded by a nucleotide sequence with deletion, substitution, insertion or addition of one or several nucleotides in SEQ ID NO: 1;', '(1A-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having at least 70% identity to the nucleotide sequence of SEQ ID NO: 1; or', '(1A-e) a protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid having a nucleotide sequence complementary to the nucleotide sequence of SEQ ID NO: 1; or', '(1B) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 17-20;, '(1) (1A) Bowman-Birk type proteinase inhibitor D-II or a variant thereof, which is defined below in any of (1A-a) to (1A-e) (2A-a) a protein comprising an amino acid sequence with deletion, substitution, insertion or addition of one or several amino acids in SEQ ID NO: 4;', '(2A-b) a protein comprising an amino acid sequence having at least 70% identity to the amino acid sequence of SEQ ID NO: 4;', '(2A-c) a protein comprising an amino acid sequence encoded by a nucleotide sequence with ...

Allergy Inhibitor Compositions And Kits And Methods Of Using The Same

Compositions, methods, and kits for inhibiting an allergic response against an allergenic protein are disclosed. Compositions, methods and kits for inhibiting an allergic response against a flea allergenic protein; a feline allergenic protein; a canine allergenic protein; a dust mite allergenic protein; a peanut allergenic protein; a Japanese cedar allergenic protein; and a blomia tropicalis allergenic protein are disclosed.

Anti-allergic medicament

The present disclosure relates to a method for the treatment of allergic conditions. In said method the allergens to which an individual is susceptible is identified as per the allergy profile and accordingly a formulation having potentized dispersions of each of the identified allergens is administered to the individual for a predetermined period and at a predetermined potency. The present disclosure also relates to a formulation which is a mixture of potentized dispersions of each of the identified allergens and the method of preparation for the same. The present disclosure further relates to a kit consisting of at least one allergen, at least one vehicle and accessories which include bottles and mixing sticks.

METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISEASES

The present invention relates to a food composition and a pharmaceutical comprising D-tryptophan. The present invention further relates to D-tryptophan for use in the treatment, prevention or amelioration of a diseases associated with Tor T2 cells, such as allergy and in particular asthma. 1. A food composition or a pharmaceutical composition comprising D-tryptophan in an amount sufficient to increase the serum level of D-tryptophan in a human subject , such that D-tryptophan peak area is increased at least 2-fold compared to the D-tryptophan peak area measured in the serum of a human subject which has not been supplemented with D-tryptophan.2. The food or pharmaceutical composition according to claim 1 , comprising one or more ingredients selected from the group consisting of an orally acceptable carrier claim 1 , sweeteners claim 1 , colorants claim 1 , preservatives claim 1 , thickeners and stabilizers claim 1 , anti-oxidants claim 1 , color fixing agents claim 1 , bleaches claim 1 , antiseptics claim 1 , gum base claim 1 , bitters claim 1 , enzymes claim 1 , brightening agents claim 1 , acidifier claim 1 , seasonings claim 1 , emulsifiers claim 1 , enhancers claim 1 , agents for manufacture claim 1 , flavors claim 1 , spice extracts claim 1 , saccharides claim 1 , starch claim 1 , inorganic materials claim 1 , plant powders claim 1 , excipients claim 1 , disintegrators claim 1 , lubricants claim 1 , binders claim 1 , surfactants claim 1 , and plasticizers.3. The food or pharmaceutical composition of configured to decrease constitutive CCL17 secretion of the cell line KM-H2 and/or preventing upregulation of costimulatory molecules of LPS-stimulated human dendritic cells.4. (canceled)5. The food or pharmaceutical composition of claim 1 , which is capable of altering the gut microbiota in a subject upon ingestion or administration.6. The food composition or pharmaceutical composition of which is a pharmaceutical composition comprising a pharmaceutical excipient.7. ...

TOFACITINIB AS VACCINATION IMMUNE MODULATOR

The invention relates to a pharmaceutical composition comprising Tofacitinib or a pharmaceutically acceptable salt thereof, and at least one antigen, allergen or autoallergen for use in medicine. Also encompassed is the use of said composition as a tolerogenic vaccine in the treatment or prevention of an immune disease. The invention further relates to Tofacitinib or a pharmaceutically acceptable salt thereof for use in tolerogenic vaccination. Another aspect of the invention is the use of Tofacitinib or a pharmaceutically acceptable salt thereof in the treatment or prevention of allergic rhinitis and/or autoimmune disease. Further the invention refers to a kit of parts comprising Tofacitinib or a pharmaceutically acceptable salt thereof, and at least one antigen or allergen. 1. A pharmaceutical composition for use in medicine , wherein said composition comprises Tofacitinib or a pharmaceutically acceptable salt thereof , and at least one antigen or allergen.2. The pharmaceutical composition for use according to claim 1 , further comprising at least one adjuvant claim 1 , preferably wherein the adjuvant is selected from monophosphoryl lipid A (MPL) claim 1 , alum or activators of dendritic cells.3. The pharmaceutical composition for use according to any one of and claim 1 , further comprising at least one pharmaceutically acceptable carrier.4. The pharmaceutical composition for use according to any one of - claim 1 , wherein the antigen is an autoantigen claim 1 , preferably wherein the autoantigen is selected from DNA components claim 1 , pancreatic islet antigens claim 1 , GAD claim 1 , insulinoma-associated antigen 2 claim 1 , insulin claim 1 , zinc transporter 8 claim 1 , RPS claim 1 , Alba-like claim 1 , p62 claim 1 , CYPs claim 1 , dUTPase claim 1 , ASGPR2 claim 1 , SMA claim 1 , matrix antigens claim 1 , citrullin claim 1 , carbamylated protein claim 1 , liver and kidney microsomal antigens claim 1 , Asialoglycoprotein receptor claim 1 , neutrophil related ...

SUBLINGUAL EPINEPHRINE TABLETS

The present disclosure provides sublingual epinephrine tablets and methods of treating anaphylaxis, methods for concomitant therapy during a cardiac event, treating hypoglycemia, and prophylaxis for immunotherapy, using sublingual epinephrine tablets.

SAFER AND MORE EFFECTIVE METHODS OF TRANSMUCOSAL, INCLUDING INTRANASAL, DELIVERY FOR RAISING BLOOD PRESSURE AND STIMULATING THE BODY

The present disclosure provides methods of mimicking epinephrine plasma pharmacokinetic parameters/plasma epinephrine levels of an at least one l-epinephrine injection in humans with an at least one dosage of an intranasal and/or sublingual l-epinephrine formulation. Methods of maintaining constant elevated plasma epinephrine level(s) by the consecutive dosing of intranasal and/or sublingual l-epinephrine are also provided. These methods may be helpful when l-epinephrine injection is not available or not possible. The present disclosure allows formulations for intranasal administration of l-epinephrine and/or small, l-epinephrine sublingual tablets to be conveniently carried by soldiers and others, such as in a remote location or battlefield, and such as when emergency medical services are not readily available or accessible. The methods may be able to sustain life and restore proper blood perfusion when someone is having cardiopulmonary difficulty until medical help or transport can arrive. 1. A method of elevating plasma epinephrine levels , the method comprising:providing at least a first dosage and a second dosage of an at least one intranasal l-epinephrine formulation to a patient by dispensing said first dosage and said second dosage of said at least one intranasal l-epinephrine formulation from an at least one dispensing container into or past at least one of said patient's nostrils to deliver said first dosage and said second dosage intranasally,wherein the at least one intranasal l-epinephrine formulation is adapted for transmucosal absorption, andat least one of blood pressure, pulse, and breathing is maintained in the patient.2. The method of claim 1 , wherein the first dosage and the second dosage are provided at least five minutes apart.3. The method of claim 1 , wherein said patient is experiencing at least one of severe allergy claim 1 , anaphylaxis claim 1 , anaphylactic shock claim 1 , sepsis claim 1 , septic shock claim 1 , respiratory difficulty ...

Substance for Treating and/or Preventing Intolerance Diseases, and Design Method and Preparation Method thereof

The present invention discloses a substance for treating and/or preventing intolerance diseases and a design method and preparation method thereof. The stable structure corresponding to the substance related to the intolerance disease is used as the substance for treating and/or preventing the intolerance disease. The essence of disease is the imbalance of biological structure system. The imbalance of the structure of the substance in the biological structure system will cause diseases related to said substance. The present disclosure relates to the treatment and/or prevention of the intolerance disease by recognizing the stable structure corresponding to the substance by the body, adjusting the expression of its gene expression or genes by the self-adaptation, self-organization and other functions of body's structural system, and restoring the balance of the structure of the substance in the biological structure system. 1129.-. (canceled)130. A method for designing substances for treating and/or preventing intolerance diseases , characterized in that:the stable structure corresponding to the substance related to the intolerance disease is used as the substance for treating and/or preventing said intolerance disease; andthe stable structure corresponding to the substance is characterized by the structure of said substance that exists in a solid state at a temperature of 500° C. or higher.131. The method according to claim 130 , characterized in that said stable structure corresponding to the substance related to the intolerance disease is selected from one or more of the following:(1) the stable structure corresponding to the substance that causes intolerance disease in the organism;(2) the stable structure corresponding to the substance of the organism itself and related to intolerance disease;(3) the stable structure corresponding to the substance that inhibits the structure that causes intolerance disease;(4) the stable structure corresponding to the substance ...

COMPOSITION FOR DIAGNOSING ALLERGIES TO MITES, METHOD OF DIAGNOSING ALLERGIES TO MITES, AND COMPOSITION FOR PREVENTING OR TREATING ALLERGIES TO MITES

Mite proteins according to an aspect may be used in diagnosing allergic diseases. Results of diagnosing allergic diseases by using the proteins have high reliability and validity. Further, the proteins may be used in a composition for preventing or treating allergic diseases. 1. A method of diagnosing an allergic disease to at least one mite species , the method comprising:detecting binding of Der f 11, Der f 13, Der f 14, Der f 32, Der f Alt a 10, or a combination thereof and IgE antibodies in a biological sample isolated from a subject;diagnosing with an allergic disease to at least one mite species when a binding between the IgE antibody and Der f 11, Der f 13, Der f 14, Der f 32, Der f Alt a 10, or a combination thereof is detected,administrating an effective amount of Der f 11, Der f 13, Der f 14, Der f 32, Der f Alt a 10, or a combination thereof to the subject diagnosed with the allergic disease to at least one mite species.2. The method of claim 1 , wherein the Der f 11 claim 1 , Der f 13 claim 1 , Der f 14 claim 1 , Der f 32 claim 1 , Der f Alt a 10 claim 1 , or a combination thereof comprises an amino acid sequence having about 95% or more sequence homology with any one amino acid sequence selected from SEQ ID NOS: 1 claim 1 , 3 claim 1 , 5 claim 1 , 7 claim 1 , and 9.3. The method of claim 1 , further comprising detecting binding of Der f 1 claim 1 , Der f 2 claim 1 , Der f 10 claim 1 , Der f 30 claim 1 , or a combination thereof and IgE antibodies in the biological sample.4. The method of claim 3 , wherein the Der f 1 claim 3 , Der f 2 claim 3 , Der f 10 claim 3 , Der f 30 claim 3 , or a combination thereof comprises an amino acid sequence having about 95% or more sequence homology with any one amino acid sequence selected from SEQ ID NOS: 11 claim 3 , 13 claim 3 , 15 claim 3 , and 17.5. The method of claim 1 , wherein the detecting is performed by immunoassay.6Dermatophagoides farinae, Dermatophagoides pteronyssinus, Euroglyphus maynei, Tyrophagus ...

Method for Therapeutic Replenishment and Enrichment of Ocular Surface Lubrication

The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or an undesired condition that is associated with or causes discomfort at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, or a lubricating fragment thereof, suspended in an ophthalmically acceptable vehicle. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.

Molecules inhibiting a metabolic pathway involving the syk protein tyrosine kinase and method for identifying said molecules

The present invention relates to the C-13 molecule (methyl 2-{5-[(3-benzyl-4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl]-2-furyl}-benzoate) and to organic molecules functionally equivalent to the C-13 molecule, capable of inhibiting the binding of an antibody or antibody fragment with the human Syk protein tyrosine kinase, to the use of these molecules for the production of medicaments for the prevention or treatment of diseases dependent on metabolic pathways involving Syk, and also to a method for identifying such molecules.

DOSING REGIMEN FOR INJECTABLE CETIRIZINE

Described herein is a method of administering injectable cetirizine or levocetirizine including intravenously injecting a mammal in need thereof with a therapeutically effective amount of an injectable cetirizine or levocetirizine composition, wherein the mammal receives a maximum daily dose of the cetirizine or levocetirizine that is no more than 15 times a maximum recommended daily clinical dose for the mammal. 127-. (canceled)28. A method of administering injectable cetirizine or levocetirizine , comprising intravenously injecting a mammalian subject in need thereof with an effective amount of an injectable cetirizine or levocetirizine composition , wherein a maximum daily dose of the cetirizine or levocetirizine is a human equivalent dose of 13 mg/kg in rats , or 2.1 mg/kg , or 15 times the maximum recommended human clinical dose.29. The method of claim 28 , wherein the therapeutically effective amount of the injectable cetirizine or levocetirizine composition is greater than the maximum recommended daily clinical dose for the mammal.30. The method of claim 28 , wherein the maximum daily dose of the cetirizine or levocetirizine is an intentional or an unintentional overdose.31. The method of claim 28 , wherein the mammal is a human subject.32. The method of claim 31 , wherein the maximum recommended human daily clinical dose is 2.5 claim 31 , 5 or 10 mg of cetirizine dihydrochloride administered once daily.33. The method of claim 32 , wherein the human subject is a child 6 months to 5 years and the maximum recommended human daily clinical dose of cetirizine dihydrochloride is 2.5 mg; the human subject is a child 6 to 11 years and the recommended human daily clinical dose of cetirizine dihydrochloride is 5 or 10 mg; or the human subject is an adult of adolescent 12 years or older and the maximum recommended daily clinical dose of cetirizine dihydrochloride is 10 mg.34. The method of claim 31 , wherein the maximum recommended human daily clinical dose is 1.25 ...

DOSING REGIMEN FOR INJECTABLE CETIRIZINE

Described herein is a method of administering injectable cetirizine or levocetirizine including intravenously injecting a mammal in need thereof with a therapeutically effective amount of an injectable cetirizine or levocetirizine composition, wherein the mammal receives a maximum daily dose of the cetirizine or levocetirizine that is no more than 15 times a maximum recommended daily clinical dose for the mammal. 1. A method of administering injectable cetirizine or levocetirizine to treat acute urticaria , comprisingintravenously injecting a human patient in an emergency department or clinic with a therapeutically effective amount of an injectable cetirizine or levocetirizine composition,determining, by the patient, a patient rated pruritus severity score at baseline and at a 1 hour assessment, anda physician determining readiness to discharge as effective treatment of the acute urticaria based on the patient rated pruritus score reduction of at least 1 unit at the 1 hour assessment compared to the baseline assessment, wherein the human patient spends 1.7±0.9 hours in the emergency department or clinic.2. The method of claim 1 , wherein the therapeutically effective amount is the maximum recommended daily clinical dose.3. The method of claim 2 , wherein the maximum recommended human daily clinical dose is 2.5 claim 2 , 5 or 10 mg of cetirizine dihydrochloride administered once daily.4. The method of claim 3 , wherein the human subject is a child 6 months to 5 years and the maximum recommended human daily clinical dose of cetirizine dihydrochloride is 2.5 mg; the human subject is a child 6 to 11 years and the recommended human daily clinical dose of cetirizine dihydrochloride is 5 or 10 mg; or the human subject is an adult of adolescent 12 years or older and the maximum recommended daily clinical dose of cetirizine dihydrochloride is 10 mg.5. The method of claim 2 , wherein the maximum recommended human daily clinical dose is 1.25 claim 2 , 2.5 or 5 mg of ...

METHODS OF TREATING HYPOGONADISM WITH TRANSNASAL TESTOSTERONE BIO-ADHESIVE GEL FORMULATIONS IN MALE WITH ALLERGIC RHINITIS, AND METHODS FOR PREVENTING AN ALLERGIC RHINITIS EVENT

The present invention relates to methods of treating hypogonadism in a male subject through administering intranasally to the male subject an intranasal testosterone bio-adhesive gel formulation to deliver a therapeutically effective amount of testosterone. In particular, the testosterone therapy of the invention remains effective if an allergic rhinitis event occurs in the male during the treatment or when the male subject uses a topical nasal vasoconstrictor or a topical intranasal decongestant during the hypogonadism treatment. Further, the present invention relates to a method of preventing the occurrence of an allergic rhinitis event in a male, who is undergoing a hypogonadism treatment with an intranasal testosterone bio-adhesive gel. In certain embodiments, the intranasal testosterone bio-adhesive gel formulation according to the invention comprises 4.0% and 4.5% testosterone. 1. A method of treating a male , who is experiencing symptomatic allergic or seasonal rhinitis , with testosterone replacement therapy for a condition associated with a deficiency or absence of endogenous who is in need of such testosterone replacement treatment , the method comprising:administering intranasally to the symptomatic male three times a day an intranasal testosterone gel to deliver intranasally to the symptomatic male a total daily dose of about 33 mg of testosterone to effectively treat said condition in the symptomatic male wherein said condition is hypogonadism.2. The intranasal testosterone method claim 1 , wherein the intranasal method includes the further step of:intranasally administering to the symptomatic male nasal vasoconstrictor and/or a nasal decongestant to intranasally treat the symptomatic male with a combination of the testosterone and the nasal vasoconstrictor and/or nasal decongestant.3. The intranasal testosterone method of claim 2 , wherein said nasal vasoconstrictor or said nasal decongestant comprises a therapeutic agent selected from the group of ...

Variant nucleic acid libraries for crth2

Provided herein are methods and compositions relating to prostaglandin D2 receptor 2 (DP2 or CRTH2R) libraries having nucleic acids encoding for a scaffold comprising a CRTH2R binding domain. CRTH2R libraries described herein encode for immunoglobulins including antibodies and single domain antibodies. Libraries described herein include variegated libraries comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein.

Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy

The present invention relates to a hydrochloride salt of a peptide consisting of the sequence of CPAVKRDVDLFLT (SEQ ID NO: 1) as well as its combinations with other peptides for immunosuppressive purposes.

A novel compound (KS-513) isolated from Pseudolysimachion rotundum var. subintegrum, the composition comprising the same preventing or treating allergic disease, inflammatory disease, asthma or chronic obstructive pulmonary disease and the use thereof

(1aS,1bS,2S,4S,5aR,6S,6aS)-1a-(hydroxymethyl)-4-methoxy-2-(((2S,3R,5S5,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)octahydrooxireno[2′,3′:4,5]cyclopenta[1,2-c]pyran-6-yl 4-hydroxybenzoate}, the isomer thereof, the pharmaceutically acceptable salt or solvates thereof, a composition comprising the same as an active ingredient for treating allergic disease, inflammatory disease, asthma or chronic obstructive pulmonary disease (COPD) and the use thereof. 2Pseudolysimachion rotundumsubintegrum. A pharmaceutical composition comprising the compound (KS513) claim 1 , the isomer thereof claim 1 , the pharmaceutically acceptable salt or solvates thereof as set forth in isolated from var to treat allergic disease claim 1 , inflammatory disease claim 1 , asthma or chronic obstructive pulmonary disease (COPD).3Pseudolysimachion rotundumsubintegrum. A pharmaceutical composition comprising the compound (KS513) isolated from the extract of var as set forth in and the pharmaceutically acceptable carriers or excipients claim 1 , for the treatment of allergic disease claim 1 , inflammatory disease claim 1 , asthma or chronic obstructive pulmonary disease (COPD).4. A method of treating allergic disease claim 1 , inflammatory disease claim 1 , asthma or chronic obstructive pulmonary disease (COPD) in mammals claim 1 , wherein the method comprises administering a therapeutically effective amount of the novel compound (KS513) claim 1 , the isomer thereof claim 1 , the pharmaceutically acceptable salt or solvates thereof as set forth in into the mammal suffering from allergic disease claim 1 , inflammatory disease claim 1 , asthma or chronic obstructive pulmonary disease (COPD).5. (canceled)6. A health functional food comprising a therapeutically effective amount of the compound (KS513) claim 1 , the isomer thereof claim 1 , the pharmaceutically acceptable salt or solvates thereof as set forth in as an active ingredients for the alleviation of allergic disease claim ...

Anti-human cd69 antibody, and use thereof for medical purposes

The present invention provides an antibody that specifically binds to human CD69, has an activity to suppress allergic inflammation, and has cross-reactivity with mouse CD69. In addition, the present invention provides an antibody having high binding affinity for human CD69 and an activity to suppress allergic inflammations. The antibody of the present invention can be a human antibody.

IGE CH3 Peptide Vaccine

The present invention relates to the provision of novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier, compositions comprising the immunogens, and methods for the prevention, treatment or alleviation of IgE-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine.